

GenCore version 5.1.6
Copyright (c) 1993 - 2003 CompuGen Ltd.

OM nucleic - nucleic search, using sw model

Run on: August 23, 2003, 11:37:06 ; Search time 342 Seconds
(without alignments)
12257.974 Million cells: updates/sec

Title: US-09-745-506-74

Perfect score: 1553
Sequence: 1 GTGATGCTATCTGCTGCT.....TCCTGTTACTTACATTCAA 1553

Scoring table: IDENTITY_NUC
Gapop 10.0 , Gapext 1.0

Searched: 2552756 segs, 1349719017 residues

Total number of hits satisfying chosen parameters: 5105512

Minimum DB seq length: 0
Maximum DB seq length: 2000000000

Post-processing: Minimum Match 0%
Maximum Match 100%

Listing first 45 summaries

Database :

N_Geneseq_19Jun03:.*
1: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1980.DAT.*
2: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1981.DAT.*
3: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1982.DAT.*
4: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1983.DAT.*
5: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1984.DAT.*
6: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1985.DAT.*
7: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1986.DAT.*
8: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1987.DAT.*
9: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1988.DAT.*
10: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1989.DAT.*
11: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1990.DAT.*
12: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1991.DAT.*
13: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1992.DAT.*
14: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1993.DAT.*
15: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1994.DAT.*
16: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1995.DAT.*
17: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1996.DAT.*
18: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1997.DAT.*
19: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1998.DAT.*
20: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA1999.DAT.*
21: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA2000.DAT.*
22: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA2001A.DAT.*
23: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA2001B.DAT.*
24: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA2002.DAT.*
25: /SIDSL/gcgdata/geneseq/geneseqn-emb1/NA2003.DAT.*

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed, and is derived by analysis of the total score distribution.

SUMMARIES

| Result No. | Score | Query Match | Length | DB ID | Description |
|------------|--------|-------------|--------|-------|-------------|
| 1 | 1524 | 98.1 | 1739 | 23 | ABV23243 |
| 2 | 1524 | 98.1 | 1739 | 23 | ABV29087 |
| 3 | 1515 | 97.6 | 1574 | 22 | AAH16397 |
| 4 | 1461.6 | 94.1 | 1696 | 22 | AAK60866 |
| 5 | 1404.8 | 90.5 | 1554 | 22 | AAK44644 |
| 6 | 1337.4 | 86.1 | 1398 | 22 | AAK59945 |
| 7 | 1300 | 83.7 | 1385 | 24 | ABL60919 |
| 8 | 1054 | 67.9 | 1686 | 23 | AAK55172 |

| | | | | | |
|----|-------|------|-------|----|-----------|
| 9 | 1053 | 67.8 | 1053 | 22 | AAH52212 |
| 10 | 725 | 46.7 | 796 | 22 | AAH07192 |
| 11 | 424 | 27.3 | 462 | 22 | AAH23953 |
| 12 | 417 | 26.9 | 14969 | 22 | AAK78763 |
| 13 | 396.8 | 25.6 | 514 | 22 | AAH15105 |
| 14 | 355.6 | 22.9 | 513 | 22 | AAK44816 |
| 15 | 288.2 | 18.6 | 394 | 25 | ABK45683 |
| 16 | 284 | 18.3 | 463 | 22 | AAK63571 |
| 17 | 265 | 17.1 | 495 | 23 | AAK55169 |
| 18 | 224.8 | 14.5 | 249 | 23 | AAK55260 |
| 19 | 220.4 | 14.2 | 465 | 22 | ABA46423 |
| 20 | 220.4 | 14.2 | 465 | 22 | ABA57019 |
| 21 | 220.4 | 14.2 | 465 | 22 | AAK05073 |
| 22 | 220.4 | 14.2 | 465 | 22 | AAH15235 |
| 23 | 220.4 | 14.2 | 465 | 22 | AAH04973 |
| 24 | 220.4 | 14.2 | 465 | 23 | ABK50297 |
| 25 | 208 | 13.4 | 208 | 22 | ABA51524 |
| 26 | 208 | 13.4 | 208 | 22 | ABA69581 |
| 27 | 208 | 13.4 | 208 | 22 | AAK17792 |
| 28 | 208 | 13.4 | 208 | 22 | AAH24414 |
| 29 | 208 | 13.4 | 208 | 22 | AAH09950 |
| 30 | 208 | 13.4 | 208 | 23 | ABA543283 |
| 31 | 189.2 | 12.2 | 633 | 22 | AAK34287 |
| 32 | 188.4 | 12.1 | 591 | 23 | ABV42397 |
| 33 | 188.4 | 12.1 | 720 | 23 | ABV22093 |
| 34 | 188.4 | 12.1 | 720 | 23 | ABV22203 |
| 35 | 188.4 | 12.1 | 720 | 23 | ABV27892 |
| 36 | 188.4 | 12.1 | 720 | 23 | ABV27933 |
| 37 | 188.4 | 12.1 | 720 | 23 | ABV28038 |
| 38 | 186.8 | 12.0 | 370 | 23 | AAK55170 |
| 39 | 165.8 | 10.7 | 510 | 23 | ABV03161 |
| 40 | 156.6 | 10.1 | 522 | 23 | AAK55171 |
| 41 | 134.2 | 8.6 | 357 | 23 | AAK55124 |
| 42 | 114.6 | 7.4 | 443 | 23 | ABV14293 |
| 43 | 113.8 | 7.3 | 273 | 23 | ABV53580 |
| 44 | 113.8 | 7.3 | 273 | 23 | ABV44212 |
| 45 | 108.4 | 7.0 | 1011 | 23 | ABL07427 |

ALIGNMENTS

| | |
|----------|---|
| RESULT 1 | |
| ABV23243 | |
| ID | ABV23243 standard; cDNA; 1739 BP. |
| XX | |
| AC | ABV23243; |
| XX | |
| DT | 16-SEP-2002 (first entry) |
| XX | |
| DE | Human prostate expression marker cDNA 23234. |
| XX | |
| KW | Human; prostate cancer; cytostatic; carcinogen; pharmacodynamic marker; |
| KW | pharmacogenomic marker; gene; ss. |
| XX | |
| OS | Homo sapiens. |
| XX | |
| PN | WO200160860-A2. |
| XX | |
| PD | 23-AUG-2001. |
| XX | |
| PF | 20-FEB-2001; 2001WO-US05171. |
| XX | |
| PR | 17-FEB-2000; 2000US-183319P. |
| PR | 16-MAR-2000; 2000US-189862P. |
| PR | 25-MAY-2000; 2000US-207454P. |
| PR | 09-JUN-2000; 2000US-211314P. |
| PR | 18-JUL-2000; 2000US-219007P. |
| PR | 13-DEC-2000; 2000US-255281P. |
| PA | (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC. |
| XX | |
| PI | Schlegel R, Endege WO, Monahan JE; |

| Db | 1431 | GTGGTTCCAGAGATGTCCTTCGAGGGATACATCACTTCGGTGTGTAATCTTATACCC | 1430 |
|----|------|--|-------|
| Qy | 1441 | AAAGTCCTACGCTCGTAAGCTAAACCTGTAATATATACCTACCATATTAAATTAACAATG | 15000 |
| Db | 1491 | AAAGTCTCTACGGCTCGTAAGGTAAACCTGTAATATATACCTACCATATTAAATTAACAATG | 15500 |
| Qy | 1501 | TTTCATTAATAACTCTAGAAAAGATTGAATAAATCTGTTACTTAACA | 1548 |
| Db | 1551 | TTTCATTAATAACTCTAGAAAAGATTGAATAAATCTGTTACTTAACA | 1598 |

RESULT 3

ID AAH16397 standard; cDNA; 1574 BP.

AC ААН16397;

DT 26-JUN-2001 (first entry)

| DE | Human | CDNA | sequence | SEQ | ID | NO:15359 |
|----|-------|------|----------|-----|----|----------|
| DE | Human | CDNA | sequence | SEQ | ID | NO:15359 |

Human; primer; detection; diagnosis; antisense therapy; gene therapy; ss.

OS Homo sapiens.

PN EP1074617-A2.

PD 07-FEB-2001.
xy

PE 28-JUL-2000; 2000EP-0116126
 YY

PR 29-JUL-1999; 99JP-0248036;
PB 37-AUG-1999; 99TD-0300353

PR 11-JAN-2000; 2000JP-0118776
03-MAY-2000; 2000JD-0183767

PR 09-JUN-2000; 2000JP-0241899
YY

PA (HELL-) HELIX RES INST.
XX

PI Ota T, Isogai T, Nishikawa T, Ishida S, Sugawara M, Nakaseki H

XX
DB WPT: 2001-318749/34

[illegible]

PT full length cDNAs defined in the specification, and for and/or diagnosis of the abnormality of the protein encoded

PI FULL-length cDNAs -
XX

PS CLAIM 8; SEQ ID 15359; 253/PP + CD ROM; English
XX

CC The present invention describes primer sets for synthesizing 5602
CC full-length cDNAs defined in the specification. Where a primer set
CC comprises: (a) an oligo-dT primer and an oligonucleotide complementary
CC to the complementary strand of a polynucleotide which comprises one of
CC the 5602 nucleotide sequences defined in the specification, where the
CC oligonucleotide comprises at least 15 nucleotides; or (b) a combination
CC of an oligonucleotide comprising a sequence complementary to the
CC complementary strand of a polynucleotide which comprises a 5'-end
CC sequence and an oligonucleotide comprising a sequence complementary to a
CC polynucleotide which comprises a 3'-end sequence, where the
CC oligonucleotide comprises at least 15 nucleotides and the combination of
CC the 5'-end sequence/3'-end sequence is selected from those defined in
CC the specification. The primer sets can be used in antisense therapy and
CC in gene therapy. The primers are useful for synthesizing polynucleotides
CC particularly full-length cDNAs. The primers are also useful for the
CC detection and/or diagnosis of the abnormality of the proteins encoded by
CC the full-length cDNAs. The primers allow obtaining of the full-length
CC cDNAs easily without any specialised methods. AAH03166 to AAH13628 and
CC AAH13633 to AAH18742 represent human cDNA sequences; AA982446 to
CC AA985893 represent human amino acid sequences; and AAH13629 to AAH13632
CC represent oligonucleotides, all of which are used in the exemplification
CC of the present invention.

| | | | |
|----------|---|---|------|
| Db | 987 | TGATCGAATATAAAGACACCTTAAACATATCTCATATTCCGTTAGCCCTTGCGGGGGAG | 1046 |
| Oy | 1021 | AACCTTAGAGTCTCAAGTCAAAAGTCGAGGCCCTGTGCTGTTCTTGAGACACGTTCT | 1080 |
| Db | 1047 | AACCTTAGAGTCTCAAGTCAAAAGTCGAGGCCCTGTGCTGTTCTTGAGACACGTTCT | 1106 |
| Oy | 1081 | GCAGGCGTTTAGGCTGACCTTTACCTTCACAGGAGGATGTCCTCATCATGTTTGA | 1140 |
| Db | 1107 | GCAGGCGTTTAGGCTGACCTTTACCTTCACAGGAGGATGTCCTCATCATGTTTGA | 1166 |
| Oy | 1141 | TGCTGCTTCCCAAGGAATAAATGTCATCCCTGTGAACACAGCAACACTGACGAGCCT | 1200 |
| Db | 1167 | TGCTGCTTCCCAAGGAATAAATGTCATCCCTGTGAACACAGCAACACTGACGAGCCT | 1226 |
| Oy | 1201 | TCCTTCTGACCTTCGAGATATGCTGATCTTCACCTTGAGAGATAAGATAATATATCT | 1260 |
| Db | 1227 | TCCTTCTGACCTTCGAGATATGCTGATCTTCACCTTGAGAGATAAGATAATATATCT | 1286 |
| Oy | 1261 | ATCAGAGACTACAGGGGACCCCTCTCAGGTGGTAAATTCGAGAAACATCGATPACAC | 1320 |
| Db | 1287 | ATCAGAGACTACAGGGGACCCCTCTCAGGTGGTAAATTCGAGAAACATCGATPACAC | 1346 |
| Oy | 1321 | ATTCCTACAAATCAGCTGGATGCCCACTTAAATTTGTAAACATGACGAGGAGCTGCT | 1380 |
| Db | 1347 | ATT-CTCAAAATCAGCTGGATG-CCAACTTAAATTTGTAAACATGACGAGGAGCTGCT | 1404 |
| Oy | 1381 | GTGCTTCCAGAGATGTCCTTGAGAGGATCATCATTTCCGGTTTGTTAATTTATTACAC | 1440 |
| Db | 1405 | GTGCTTCCAGAGATGTCCTTGAGAGGATCATCATTTCCGGTTTGTTAATTTATTACAC | 1464 |
| Oy | 1441 | AAATGTTCTAAGCTCGTAAGGTAAACTGTAAATATTAACCTCAATATTAATTAACAATG | 1500 |
| Db | 1465 | AAATGTTCTAAGCTCGTAAGGTAAACTGTAAATATTAACCTCAATATTAATTAACAATG | 1524 |
| Oy | 1501 | TTCAATTAACTCTAGGAAGATTGAATATAAATCTGTTACTTAACATTG | 1551 |
| Db | 1525 | TTCAATTAACTCTAGGAAGATTGAATATAAATCTGTTACTTAACATTG | 1574 |
| RESULT 4 | | | |
| AAK60866 | | | |
| ID | AAK60866 | standard; cdna; 1696 bp. | |
| XX | AAK60866; | | |
| XX | | | |
| XX | 06-NOV-2001 (first entry) | | |
| DE | Human immune/haematopoietic antigen encoding cdna seq ID NC:5926. | | |
| KW | Human; immune; haematopoietic; immune/haematopoietic antigen; cancer; | | |
| KW | cytostatic; gene therapy; vaccine; metastasis; ss. | | |
| XX | Homo sapiens. | | |
| OS | | | |
| XX | W0200157182-A2. | | |
| XX | | | |
| XX | 09-AUG-2001. | | |
| XX | | | |
| XX | 17-JAN-2001; 2001WO-US01354. | | |
| PR | 31-JAN-2000; 2000US-0179065. | | |
| PR | 04-FEB-2000; 2000US-0180628. | | |
| PR | 24-FEB-2000; 2000US-0184684. | | |
| PR | 02-MAR-2000; 2000US-0186350. | | |
| PR | 16-MAR-2000; 2000US-0189874. | | |
| PR | 17-MAR-2000; 2000US-0190076. | | |
| PR | 18-APR-2000; 2000US-0198123. | | |
| PR | 19-MAY-2000; 2000US-0205515. | | |
| PR | 07-JUN-2000; 2000US-0209467. | | |
| PR | 28-JUN-2000; 2000US-0214886. | | |
| PR | 30-JUN-2000; 2000US-0215135. | | |
| PR | 07-JUL-2000; 2000US-0216647. | | |
| PR | 07-JUL-2000; 2000US-0216880. | | |

| | | |
|----|-------------|----------------|
| PR | 11-JUL-2000 | 2000US-0217487 |
| PR | 11-JUL-2000 | 2000US-0217486 |
| PR | 14-JUL-2000 | 2000US-0218249 |
| PR | 26-JUL-2000 | 2000US-0220964 |
| PR | 26-JUL-2000 | 2000US-0220963 |
| PR | 14-AUG-2000 | 2000US-0224518 |
| PR | 14-AUG-2000 | 2000US-0224513 |
| PR | 14-AUG-2000 | 2000US-0225213 |
| PR | 14-AUG-2000 | 2000US-0225216 |
| PR | 14-AUG-2000 | 2000US-0225264 |
| PR | 14-AUG-2000 | 2000US-0225268 |
| PR | 14-AUG-2000 | 2000US-0225267 |
| PR | 14-AUG-2000 | 2000US-0225270 |
| PR | 14-AUG-2000 | 2000US-0225347 |
| PR | 14-AUG-2000 | 2000US-0225357 |
| PR | 14-AUG-2000 | 2000US-0225758 |
| PR | 14-AUG-2000 | 2000US-0225759 |
| PR | 18-AUG-2000 | 2000US-0226279 |
| PR | 22-AUG-2000 | 2000US-0226661 |
| PR | 22-AUG-2000 | 2000US-0226688 |
| PR | 23-AUG-2000 | 2000US-0227182 |
| PR | 30-AUG-2000 | 2000US-0228942 |
| PR | 01-SEP-2000 | 2000US-0229287 |
| PR | 01-SEP-2000 | 2000US-0229343 |
| PR | 01-SEP-2000 | 2000US-0229344 |
| PR | 01-SEP-2000 | 2000US-0229345 |
| PR | 05-SEP-2000 | 2000US-0229513 |
| PR | 05-SEP-2000 | 2000US-0229513 |
| PR | 06-SEP-2000 | 2000US-0230437 |
| PR | 06-SEP-2000 | 2000US-0230438 |
| PR | 08-SEP-2000 | 2000US-0231242 |
| PR | 08-SEP-2000 | 2000US-0231243 |
| PR | 08-SEP-2000 | 2000US-0231244 |
| PR | 08-SEP-2000 | 2000US-0231245 |
| PR | 08-SEP-2000 | 2000US-0231413 |
| PR | 08-SEP-2000 | 2000US-0231414 |
| PR | 08-SEP-2000 | 2000US-0232080 |
| PR | 08-SEP-2000 | 2000US-0232081 |
| PR | 12-SEP-2000 | 2000US-0232198 |
| PR | 14-SEP-2000 | 2000US-0232397 |
| PR | 14-SEP-2000 | 2000US-0232398 |
| PR | 14-SEP-2000 | 2000US-0232399 |
| PR | 14-SEP-2000 | 2000US-0232400 |
| PR | 14-SEP-2000 | 2000US-0232401 |
| PR | 14-SEP-2000 | 2000US-0232403 |
| PR | 14-SEP-2000 | 2000US-0232405 |
| PR | 14-SEP-2000 | 2000US-0232406 |
| PR | 14-SEP-2000 | 2000US-0232407 |
| PR | 21-SEP-2000 | 2000US-0234223 |
| PR | 21-SEP-2000 | 2000US-0234224 |
| PR | 25-SEP-2000 | 2000US-0234914 |
| PR | 25-SEP-2000 | 2000US-0234917 |
| PR | 25-SEP-2000 | 2000US-0234918 |
| PR | 26-SEP-2000 | 2000US-0235448 |
| PR | 27-SEP-2000 | 2000US-0235834 |
| PR | 27-SEP-2000 | 2000US-0235835 |
| PR | 29-SEP-2000 | 2000US-0236327 |
| PR | 29-SEP-2000 | 2000US-0236328 |
| PR | 29-SEP-2000 | 2000US-0236337 |
| PR | 29-SEP-2000 | 2000US-0236338 |
| PR | 29-SEP-2000 | 2000US-0236339 |
| PR | 29-SEP-2000 | 2000US-0236340 |
| PR | 29-SEP-2000 | 2000US-0236341 |
| PR | 29-SEP-2000 | 2000US-0236342 |
| PR | 29-SEP-2000 | 2000US-0236343 |
| PR | 29-SEP-2000 | 2000US-0236344 |
| PR | 29-SEP-2000 | 2000US-0236345 |
| PR | 29-SEP-2000 | 2000US-0236346 |
| PR | 29-SEP-2000 | 2000US-0236347 |
| PR | 29-SEP-2000 | 2000US-0236348 |
| PR | 29-SEP-2000 | 2000US-0236349 |
| PR | 29-SEP-2000 | 2000US-0236350 |
| PR | 29-SEP-2000 | 2000US-0236351 |
| PR | 29-SEP-2000 | 2000US-0236352 |
| PR | 29-SEP-2000 | 2000US-0236353 |
| PR | 29-SEP-2000 | 2000US-0236354 |
| PR | 29-SEP-2000 | 2000US-0236355 |
| PR | 29-SEP-2000 | 2000US-0236356 |
| PR | 29-SEP-2000 | 2000US-0236357 |
| PR | 29-SEP-2000 | 2000US-0236358 |
| PR | 29-SEP-2000 | 2000US-0236359 |
| PR | 29-SEP-2000 | 2000US-0236360 |
| PR | 29-SEP-2000 | 2000US-0236361 |
| PR | 29-SEP-2000 | 2000US-0236362 |
| PR | 29-SEP-2000 | 2000US-0236363 |
| PR | 29-SEP-2000 | 2000US-0236364 |
| PR | 29-SEP-2000 | 2000US-0236365 |
| PR | 29-SEP-2000 | 2000US-0236366 |
| PR | 29-SEP-2000 | 2000US-0236367 |
| PR | 29-SEP-2000 | 2000US-0236368 |
| PR | 29-SEP-2000 | 2000US-0236369 |
| PR | 29-SEP-2000 | 2000US-0236370 |
| PR | 29-SEP-2000 | 2000US-0236371 |
| PR | 29-SEP-2000 | 2000US-0236372 |
| PR | 29-SEP-2000 | 2000US-0236373 |
| PR | 29-SEP-2000 | 2000US-0236374 |
| PR | 29-SEP-2000 | 2000US-0236375 |
| PR | 29-SEP-2000 | 2000US-0236376 |
| PR | 29-SEP-2000 | 2000US-0236377 |
| PR | 29-SEP-2000 | 2000US-0236378 |
| PR | 29-SEP-2000 | 2000US-0236379 |
| PR | 29-SEP-2000 | 2000US-0236380 |
| PR | 29-SEP-2000 | 2000US-0236381 |
| PR | 29-SEP-2000 | 2000US-0236382 |
| PR | 29-SEP-2000 | 2000US-0236383 |
| PR | 29-SEP-2000 | 2000US-0236384 |
| PR | 29-SEP-2000 | 2000US-0236385 |
| PR | 29-SEP-2000 | 2000US-0236386 |
| PR | 29-SEP-2000 | 2000US-0236387 |
| PR | 29-SEP-2000 | 2000US-0236388 |
| PR | 29-SEP-2000 | 2000US-0236389 |
| PR | 29-SEP-2000 | 2000US-0236390 |
| PR | 29-SEP-2000 | 2000US-0236391 |
| PR | 29-SEP-2000 | 2000US-0236392 |
| PR | 29-SEP-2000 | 2000US-0236393 |
| PR | 29-SEP-2000 | 2000US-0236394 |
| PR | 29-SEP-2000 | 2000US-0236395 |
| PR | 29-SEP-2000 | 2000US-0236396 |
| PR | 29-SEP-2000 | 2000US-0236397 |
| PR | 29-SEP-2000 | 2000US-0236398 |
| PR | 29-SEP-2000 | 2000US-0236399 |
| PR | 29-SEP-2000 | 2000US-0236400 |
| PR | 29-SEP-2000 | 2000US-0236401 |
| PR | 29-SEP-2000 | 2000US-0236402 |
| PR | 29-SEP-2000 | 2000US-0236403 |
| PR | 29-SEP-2000 | 2000US-0236404 |
| PR | 29-SEP-2000 | 2000US-0236405 |
| PR | 29-SEP-2000 | 2000US-0236406 |
| PR | 29-SEP-2000 | 2000US-0236407 |
| PR | 29-SEP-2000 | 2000US-0236408 |
| PR | 29-SEP-2000 | 2000US-0236409 |
| PR | 29-SEP-2000 | 2000US-0236410 |
| PR | 29-SEP-2000 | 2000US-0236411 |
| PR | 29-SEP-2000 | 2000US-0236412 |
| PR | 29-SEP-2000 | 2000US-0236413 |
| PR | 29-SEP-2000 | 2000US-0236414 |
| PR | 29-SEP-2000 | 2000US-0236415 |
| PR | 29-SEP-2000 | 2000US-0236416 |
| PR | 29-SEP-2000 | 2000US-0236417 |
| PR | 29-SEP-2000 | 2000US-0236418 |
| PR | 29-SEP-2000 | 2000US-0236419 |
| PR | 29-SEP-2000 | 2000US-0236420 |
| PR | 29-SEP-2000 | 2000US-0236421 |
| PR | 29-SEP-2000 | 2000US-0236422 |
| PR | 29-SEP-2000 | 2000US-0236423 |
| PR | 29-SEP-2000 | 2000US-0236424 |
| PR | 29-SEP-2000 | 2000US-0236425 |
| PR | 29-SEP-2000 | 2000US-0236426 |
| PR | 29-SEP-2000 | 2000US-0236427 |
| PR | 29-SEP-2000 | 2000US-0236428 |
| PR | 29-SEP-2000 | 2000US-0236429 |
| PR | 29-SEP-2000 | 2000US-0236430 |
| PR | 29-SEP-2000 | 2000US-0236431 |
| PR | 29-SEP-2000 | 2000US-0236432 |
| PR | 29-SEP-2000 | 2000US-0236433 |
| PR | 29-SEP-2000 | 2000US-0236434 |
| PR | 29-SEP-2000 | 2000US-0236435 |
| PR | 29-SEP-2000 | 2000US-0236436 |
| PR | 29-SEP-2000 | 2000US-0236437 |
| PR | 29-SEP-2000 | 2000US-0236438 |
| PR | 29-SEP-2000 | 2000US-0236439 |
| PR | 29-SEP-2000 | 2000US-0236440 |
| PR | 29-SEP-2000 | 2000US-0236441 |
| PR | 29-SEP-2000 | 2000US-0236442 |
| PR | 29-SEP-2000 | 2000US-0236443 |
| PR | 29-SEP-2000 | 2000US-0236444 |
| PR | 29-SEP-2000 | 2000US-0236445 |
| PR | 29-SEP-2000 | 2000US-0236446 |
| PR | 29-SEP-2000 | 2000US-0236447 |
| PR | 29-SEP-2000 | 2000US-0236448 |
| PR | 29-SEP-2000 | 2000US-0236449 |
| PR | 29-SEP-2000 | 2000US-0236450 |
| PR | 29-SEP-2000 | 2000US-0236451 |
| PR | 29-SEP-2000 | 2000US-0236452 |
| PR | 29-SEP-2000 | 2000US-0236453 |
| PR | 29-SEP-2000 | 2000US-0236454 |
| PR | 29-SEP-2000 | 2000US-0236455 |
| PR | 29-SEP-2000 | 2000US-0236456 |
| PR | 29-SEP-2000 | 2000US-0236457 |
| PR | 29-SEP-2000 | 2000US-0236458 |
| PR | 29-SEP-2000 | 2000US-0236459 |
| PR | 29-SEP-2000 | 2000US-0236460 |
| PR | 29-SEP-2000 | 2000US-0236461 |
| PR | 29-SEP-2000 | 2000US-0236462 |
| PR | 29-SEP-2000 | 2000US-0236463 |
| PR | 29-SEP-2000 | 2000US-0236464 |
| PR | 29-SEP-2000 | 2000US-0236465 |
| PR | 29-SEP-2000 | 2000US-0236466 |
| PR | 29-SEP-2000 | 2000US-0236467 |
| PR | 29-SEP-2000 | 2000US-0236468 |
| PR | 29-SEP-2000 | 2000US-0236469 |
| PR | 29-SEP-2000 | 2000US-0236470 |
| PR | 29-SEP-2000 | 2000US-0236471 |
| PR | 29-SEP-2000 | 2000US-0236472 |
| PR | 29-SEP-2000 | 2000US-0236473 |
| PR | 29-SEP-2000 | 2000US-0236474 |
| PR | 29-SEP-2000 | 2000US-0236475 |
| PR | 29-SEP-2000 | 2000US-0236476 |
| PR | 29-SEP-2000 | 2000US-0236477 |
| PR | 29-SEP-2000 | 2000US-0236478 |
| PR | 29-SEP-2000 | 2000US-0236479 |
| PR | 29-SEP-2000 | 2000US-0236480 |
| PR | 29-SEP-2000 | 2000US-0236481 |
| PR | 29-SEP-2000 | 2000US-0236482 |
| PR | 29-SEP-2000 | 2000US-0236483 |
| PR | 29-SEP-2000 | 2000US-0236484 |
| PR | 29-SEP-2000 | 2000US-0236485 |
| PR | 29-SEP-2000 | 2000US-0236486 |
| PR | 29-SEP-2000 | 2000US-0236487 |
| PR | 29-SEP-2000 | 2000US-0236488 |
| PR | 29-SEP-2000 | 2000US-0236489 |
| PR | 29-SEP-2000 | 2000US-0236490 |
| PR | 29-SEP-2000 | 2000US-0236491 |
| PR | 29-SEP-2000 | 2000US-0236492 |
| PR | 29-SEP-2000 | 2000US-0236493 |
| PR | 29-SEP-2000 | 2000US-0236494 |
| PR | 29-SEP-2000 | 2000US-0236495 |
| PR | 29-SEP-2000 | 2000US-0236496 |
| PR | 29-SEP-2000 | 2000US-0236497 |
| PR | 29-SEP-2000 | 2000US-0236498 |
| PR | 29-SEP-2000 | 2000US-0236499 |
| PR | 29-SEP-2000 | 2000US-0236500 |
| PR | 29-SEP-2000 | 2000US-0236501 |
| PR | 29-SEP-2000 | 2000US-0236502 |
| PR | 29-SEP-2000 | 2000US-0236503 |
| PR | 29-SEP-2000 | 2000US-0236504 |
| PR | 29-SEP-2000 | 2000US-0236505 |
| PR | 29-SEP-2000 | 2000US-0236506 |
| PR | 29-SEP-2000 | 2000US-0236507 |
| PR | 29-SEP-2000 | 2000US-0236508 |
| PR | 29-SEP-2000 | 2000US-0236509 |
| PR | 29-SEP-2000 | 2000US-0236510 |
| PR | 29-SEP-2000 | 2000US-0236511 |
| PR | 29-SEP-2000 | 2000US-0236512 |
| PR | 29-SEP-2000 | 2000US-0236513 |
| PR | 29-SEP-2000 | 2000US-0236514 |
| PR | 29-SEP-2000 | 2000US-0236515 |
| PR | 29-SEP-2000 | 2000US-0236516 |
| PR | 29-SEP-2000 | 2000US-0236517 |
| PR | 29-SEP-2000 | 2000US-0236518 |
| PR | 29-SEP-2000 | 2000US-0236519 |
| PR | 29-SEP-2000 | 2000US-0236520 |
| PR | 29-SEP-2000 | 2000US-0236521 |
| PR | 29-SEP-2000 | 2000US-0236522 |
| PR | 29-SEP-2000 | 2000US-0236523 |
| PR | 29-SEP-2000 | 2000US-0236524 |
| PR | 29-SEP-2000 | 2000US-0236525 |
| PR | 29-SEP-2000 | 2000US-0236526 |
| PR | 29-SEP-2000 | 2000US-0236527 |
| PR | 29-SEP-2000 | 2000US-0236528 |
| PR | 29-SEP-2000 | 2000US-0236529 |
| PR | 29-SEP-2000 | 2000US-0236530 |
| PR | 29-SEP-2000 | 2000US-0236531 |
| PR | 29-SEP-2000 | 2000US-0236532 |
| PR | 29-SEP-2000 | 2000US-0236533 |
| PR | 29-SEP-2000 | 2000US-0236534 |
| PR | 29-SEP-2000 | 2000US-0236535 |
| PR | 29-SEP-2000 | 2000US-0236536 |
| PR | 29-SEP-2000 | 2000US-0236537 |
| PR | 29-SEP-2000 | 2000US-0236538 |
| PR | 29-SEP-2000 | 2000US-0236539 |
| PR | 29-SEP-2000 | 2000US-0236540 |
| PR | 29-SEP-2000 | 2000US-0236541 |
| PR | 29-SEP-2000 | 2000US-0236542 |
| PR | 29-SEP-2000 | 2000US-0236543 |
| PR | 29-SEP-2000 | 2000US-0236544 |
| PR | 29-SEP-2000 | 2000US-0236545 |
| PR | 29-SEP-2000 | 2000US-0236546 |
| PR | 29-SEP-2000 | 2000US-0236547 |
| PR | 29-SEP-2000 | 2000US-0236548 |
| PR | 29-SEP-2000 | 2000US-0236549 |
| PR | 29-SEP-2000 | 2000US-0236550 |
| PR | 29-SEP-2000 | 2000US-0236551 |
| PR | 29-SEP-2000 | 2000US-0236552 |
| PR | 29-SEP-2000 | 2000US-0236553 |
| PR | 29-SEP-2000 | 2000US-0236554 |
| PR | 29-SEP-2000 | 2000US-0236555 |
| PR | 29-SEP-2000 | 2000US-0236556 |
| PR | 29-SEP-2000 | 2000US-0236557 |
| PR | 29-SEP-2000 | 2000US-0236558 |
| PR | 29-SEP-2000 | 2000US-0236559 |
| PR | 29-SEP-2000 | 2000US-0236560 |
| PR | 29-SEP-2000 | 2000US-0236561 |
| PR | 29-SEP-2000 | 2000US-0236562 |
| PR | 29-SEP-2000 | 2000US-0236563 |
| PR | 29-SEP-2000 | 2000US-0236564 |
| PR | 29-SEP-2000 | 2000US-0236565 |
| PR | 29-SEP-2000 | 2000US-0236566 |
| PR | 29-SEP-2000 | 2000US-0236567 |
| PR | 29-SEP-2000 | 2000US-0236568 |
| PR | 29-SEP-2000 | 2000US-0236569 |
| PR | 29-SEP-2000 | 2000US-0236570 |
| PR | 29-SEP-2000 | 2000US-0236571 |
| PR | 29-SEP-2000 | 2000US-0236572 |
| PR | 29-SEP-2000 | 2000US-0236 |

[illegible]

| Query Match | 94.1% | Score 1461.6 | DB 22 | Length 1696 |
|-----------------------|----------------|--|-----------|-------------|
| Best Local Similarity | 96.4% | Pred. No. 0 | | |
| Matches 1547 | Conservative 0 | Mismatches 4 | Indels 53 | Gaps 3 |
| QY | 1 | GTGATGTTTACTTGGTGTGACAGAGACAGAGAGAGAGATTTGGGTACGAAACTGTC | 60 | |
| Db | 12 | GTGATTTCTTACTTGGTGTGACAGAGAGACAGAGAGAGATTTGGGTACGAAACTGTC | 71 | |
| QY | 61 | CTGCGCCACACAGACAGACAGCGCACTAGTGGACAGGGGCTCTGACTACCTTACTGG | 120 | |
| Db | 72 | CTGCGCCACACAGACAGACAGCGCACTAGTGGACAGGGGCTCTGACTACCTTAACTGG | 131 | |
| QY | 121 | CTGTGTCGTCTGGTTTTTTCACGTCTCTGGAAAAGCCGTGAAGTGGCACTGAAAGAGGCA | 180 | |
| Db | 132 | CTGTGTCGTCTGGTTTTTTCACGTCTCTGGAAAAGCCGTGAAGTGGCACTGAAAGAGGCA | 191 | |
| QY | 181 | TAGATG-----AGT | 189 | |
| Db | 192 | TAGATGGAACACTGAACTTACCTGATTTCTGTATGTTGTTCATCTTGCATGCCCACT | 251 | |
| QY | 190 | CCCCACGACAGTCGCGGTTGTAGATTCCTGATCTGACAACTTCTCCGCTCTCTTANTGA | 249 | |
| Db | 252 | CCCCACGACAGTCGCGGTTGTAGATTCCTGATCTGACAACTTCTCCGCTCTCTTANTGA | 311 | |
| QY | 250 | TTTGAAGGCTCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT | 309 | |
| Db | 312 | TTTGAAGGCTCTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTTCTT | 371 | |
| QY | 310 | GGACAAATGTGGATTTACTGCTGGAGAACCAAGCCACACATACCTGTAATTAACATCTTCT | 369 | |
| Db | 372 | GGACAAATGTGGATTTACTGCTGGAGAACCAAGCCACACATACCTGTAATTAACATCTTCT | 431 | |
| QY | 370 | GACCAATGACCTGACTGAGGAAGTGTAGAGAGGTCGTCTGCAAAAAGGAAGGACATCTAT | 429 | |
| Db | 432 | GACCAATGACCTGACTGAGGAAGTGTAGAGAGGTCGTCTGCAAAAAGGAAGGACATCTAT | 491 | |
| QY | 430 | TCTCTCTTACCATCCGCTTATCTTCCGACCCATGAAAGGCAATTAACCTGGAACACATGGAA | 489 | |
| Db | 492 | TCTCTCTTACCATCCGCTTATCTTCCGACCCATGAAAGGCAATTAACCTGGAACACATGGAA | 551 | |
| QY | 490 | GGAGCGCTGTGATATCCGGGCTCTGGAGAAAGAGTCCGATCTACTCTCTCTCAATACG | 549 | |
| Db | 552 | GGAGCGCTGTGATATCCGGGCTCTGGAGAAAGAGTCCGATCTACTCTCTCTCAATACG | 611 | |
| QY | 550 | CTATGATGCTGCGCCACAGGGCTCAACAACATGTGTGGCTAAAGGGCTTGAAGCTTGTAC | 609 | |
| Db | 612 | CTATGATGCTGCGCCACAGGGCTCAACAACATGTGTGGCTAAAGGGCTTGAAGCTTGTAC | 671 | |
| QY | 610 | CTCAGAGCCATACATCTTCTCCAAACACTCCCAATCTCCATACAGAGGGAACCAACGAGT | 669 | |
| Db | 672 | CTCAGAGCCATACATCTTCTCCAAACACTCCCAATCTCCATACAGAGGGAACCAACGAGT | 731 | |
| QY | 670 | AGAAATTAAGCTTAACCTACACCCAGAACCTGGACAAAGTCATGTGCAAGTGAAGAGAT | 729 | |
| Db | 732 | AGAAATTAAGCTTAACCTACACCCAGAACCTGGACAAAGTCATGTGCAAGTGAAGAGAT | 791 | |
| QY | 730 | TGACGGGTCTTCTGCTACTCTTCTTCTCTAGACTGGTAAATGAGGAACAAACGAGAT | 789 | |
| Db | 792 | TGACGGGTCTTCTGCTACTCTTCTTCTCTAGACTGGTAAATGAGGAACAAACGAGAT | 851 | |
| QY | 790 | TAAATGAAATTTGACTCAGAGGCTTGTATGACAGGTGTAGATTTCTTCTCCGGAACAA | 849 | |

Db 852 TAATGAAATGTACTAGAGAGCTTTGATGAGTGTAGATTTCTTTCCGGAACAA 911
 QY 850 ACAACTTTATCAGAGAGCAATTCGTACCTGGAGAACCTTTGCTTACATCTGG 909
 Db 912 ACACCTTTATCAGAGAGCAATTCGTACCTGGAGAACCTTTGCTTACATCTGG 971
 QY 910 AATGGAGCGTTATGACACTGATGATGATGCTCTCCGCAACATGATGATGCAAT 969
 Db 972 AATGGAGCGTTATGACACTGATGATGATGCTCTCCGCAACATGATGATGCAAT 1031
 QY 970 AAAAAACACCTTAAATCTATCTATCTGCTTACCTGGGCGGGAACCTTGA 1029
 Db 1032 AAAAAACACCTTAAATCTATCTATCTGCTTACCTGGGCGGGAACCTTGA 1091
 QY 1030 GTCTCAAGTCAAAAGTGTGGCTGTGTGCTGGGAGAGAGCTTTCGAGGTGT 1089
 Db 1092 GTCTCAAGTCAAAAGTGTGGCTGTGTGCTGGGAGAGAGCTTTCGAGGTGT 1151
 QY 1090 TGAAGCTGACCTTTACCTCAGAGTATGATGATGATGATGATGATGATGATG 1149
 Db 1152 TGAAGCTGACCTTTACCTCAGAGTATGATGATGATGATGATGATGATGATG 1211
 QY 1150 CCAAGGAATTAATGATCTCTGTGACACAGCAACACAGAGCTTTCTTCTGA 1209
 Db 1212 CCAAGGAATTAATGATCTCTGTGACACAGCAACACAGAGCTTTCTTCTGA 1271
 QY 1210 CCTTCAGATATGCTGATGATCTCAGTGGAGATTAATGATTAATTCCTATCAGAG 1269
 Db 1272 CCTTCAGATATGCTGATGATCTCAGTGGAGATTAATGATTAATTCCTATCAGAG 1331
 QY 1270 TGAAGGAGACCTTTCTCAGTGTATTAATGAGAAACATCAGATTAACATTTCTTCA 1329
 Db 1332 TGAAGGAGACCTTTCTCAGTGTATTAATGAGAAACATCAGATTAACATTTCTTCA 1390
 QY 1330 AATCAGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1389
 Db 1391 AATCAGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1449
 QY 1390 GAGAGTGTCTCGAGGATATCATCAATTCGGTTGTTATCTTATTCACCAATGTTCT 1449
 Db 1450 GAGAGTGTCTCGAGGATATCATCAATTCGGTTGTTATCTTATTCACCAATGTTCT 1509
 QY 1450 ATGCTGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1509
 Db 1510 ATGCTGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1569
 QY 1510 AACTCTAGGAAGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1553
 Db 1570 AACTCTAGGAAGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1613
 RESULT 5
 AAS44644
 ID AAS44644 standard; DNM: 1554 BP.
 AC AAS44644:
 DT 18-DEC-2001 (first entry)
 XX Human full-length polynucleotide sequence #69.
 DE
 XX
 KW Mammal; human; rhesus monkey; baker's yeast; fission yeast; Norway rat;
 KW mouse; Chinese hamster; African clawed frog; fruit fly; dog; leukemia;
 KW cancer; lymphoma; neuroblastoma; autoimmune disorder; cell proliferation;
 KW nervous system disorder; inflammatory disorder; cell differentiation; ds;
 KW angiogenesis; stem cell growth factor; activin; inhibin; cartilage; burn;
 KW genetic disorder; bone regeneration; tendon; ligament; tissue repair;
 KW cytoskeletal; antiinflammatory; antiarthritic; vulnary; antiinflammatory;
 KW antibacterial; immunosuppressive; vasotropic; antiparkinsonian;
 KW neuroprotective; osteoplastic; antiadipic; antiallergic;
 KW immunostimulant; analgesic; gene therapy.
 OS Homo sapiens.

XX
 PN W0200164834-A2.
 XX
 PD 07-SEP-2001.
 XX
 PE 26-FEB-2001; 2001WO-US04926.
 XX
 PR 28-FEB-2000; 2000US-0515126.
 PR 18-MAY-2000; 2000US-0577409.
 PR 17-JUN-2000; 2000US-0577409.
 PR 14-JUL-2000; 2000US-0616807.
 PR 19-SEP-2000; 2000US-0664641.
 XX
 PA (HYSE-) HYSED INC.
 XX
 FI Tang YT, Liu C, Zhou P, Asundi V, Zhang J, Zhao QA, Ren F;
 PI Xue AJ, Yang Y, Wehrman T, Wang J, Ma Y, Wang D, Chen R, Xu C;
 PI drmanac R;
 XX
 DR WPI: 2001-589862/66.
 DR P-Psdb: AAU27744.
 XX
 PS Claim 1; SEQ ID NO 69; 153bp; English.
 XX
 CC Sequences AAS44576-AAS44919 represent full-length polynucleotides and
 CC contig polynucleotides encoding polypeptides of the invention. The DNA
 CC and protein sequences are useful for the treatment, diagnosis and
 CC prevention of various types of disorder in a mammalian subject such as a
 CC human, dog, monkey, mouse, hamster or rat. The disorders include cancers
 CC such as leukemia, lymphoma and neuroblastoma, autoimmune disorders such
 CC as multiple sclerosis, connective tissue disease, rheumatoid arthritis,
 CC diabetes mellitus, allergic rhinitis, asthma and eczema, nervous system
 CC disorders such as Parkinson's disease, Alzheimer's disease, Huntington's
 CC chorea, amyotrophic lateral sclerosis, spinal muscular atrophy and
 CC Wernicke disease, inflammatory disorders such as nephritis, Crohn's
 CC disease, ischemia-reperfusion injury, shock, sepsis and inflammatory
 CC bowel disease. The sequences exhibit activity relating to angiogenesis,
 CC cell proliferation, cell differentiation, stem cell growth factor,
 CC activin or inhibin. Therefore, they can be used to manipulate stem cells
 CC in culture to give rise to neuroepithelial cells that can be used to
 CC augment or replace cells damaged by illness, accidental damage or genetic
 CC disorders. The sequences may also be used for regeneration of bone,
 CC cartilage, tendons and ligaments and in tissue repair and burn healing.
 CC Note: Some sequences for this patent did not form part of the printed
 CC specification, but were obtained in electronic format directly from WIP0
 CC at ftp.wip0.int/pub/published_pct_sequences.
 CC
 XX
 SQ Sequence 1554 BP; 428 A; 358 C; 346 G; 422 T; 0 other:
 Query Match 90.5%; Score 1404.8; DB 22; Length 1554;
 Best Local Similarity .96.4%; Pred. No. 0;
 Matches 1489; Conservative 0; Mismatches 2; Indels 53; Gaps 3;
 QY 61 CTTGCCCGACACAGACAGACAGCGGCTAGTGGAGAGGGGCTTACTACACTTAATCG 120
 Db 1 CTTGCCCGACACAGACAGACAGCGGCTAGTGGAGAGGGGCTTACTACACTTAATCG 60
 QY 121 CTGTGCTGCGGTTTCTCACTGCTGGAAGAGGCTGGAAGTGGCACTGAAATGAGGCA 180
 Db 61 CTGTGCTGCGGTTTCTCACTGCTGGAAGAGGCTGGAAGTGGCACTGAAATGAGGCA 120
 QY 181 TAGATG-----AGT 189
 Db 121 TAGATGGAAGAACTTGAATTTCTGATGTTGTCATCTTGGCAGCCAGT 180
 QY 190 CCCGACAGACGTCGGTTTGTAGATTCCTGATGTCGAATTTCTCCGTTCTTATGGA 249
 Db 181 CCCGACAGACGTCGGTTTGTAGATTCCTGATGTCGAATTTCTCCGTTCTTATGGA 240


```
OY 230 TTTGAGGCTCTCTTCTTCTTGAAATGATTTGCAATCCCTCTGTTTGTGAGAGTTG 309
DB 241 TTTGAGGCTCTCTTCTTCTTGAAATGATTTGCAATCCCTCTGTTTGTGAGAGTTG 300
OY 310 GGACATGTTGATTTAGTGTGGAACCAAGCCACCATCTGTAATATACCTCTCTCT 369
DB 301 GGACATGTTGATTTAGTGTGGAACCAAGCCACCATCTGTAATATACCTCTCTCT 360
OY 370 GACCAATGACCGACTGAGGAGGATGATGAGAGGTGCGCAAAAGGAGGAGCTGAT 429
DB 361 GACCAATGACCGACTGAGGAGGATGATGAGAGGTGCGCAAAAGGAGGAGCTGAT 420
OY 430 TCTCTCTACACATCCGCTATCTCTCGACCCATGGAAGCGCATACCTGGAACATGNA 489
DB 421 TCTCTCTACACATCCGCTATCTCTCGACCCATGGAAGCGCATACCTGGAACATGNA 480
OY 490 GGAGCGCTGTGATCCGGGCTCTGAGAACAGAGTCCGTAATCTCTCTCTCATACG 549
DB 481 GGAGCGCTGTGATCCGGGCTCTGAGAACAGAGTCCGTAATCTCTCTCTCATACG 540
OY 550 CTATGATGCTGGGCCCAAGGCGTCAACAAGTGTGCTAAAGGCGTGGAGCTGTAC 609
DB 541 CTATGATGCTGGGCCCAAGGCGTCAACAAGTGTGCTAAAGGCGTGGAGCTGTAC 600
OY 610 CTCCAGGCCATACATCTCTCCAAAGCTCCCACTACCTACAGAGGAAACACCGAGT 669
DB 601 CTCCAGGCCATACATCTCTCCAAAGCTCCCACTACCTACAGAGGAAACACCGAGT 660
OY 670 AGAATTCACGTTAACTACACCAAGACCTGGACAAAGTCAATGTCTGCAAGTAAGAA 729
DB 661 AGAATTCACGTTAACTACACCAAGACCTGGACAAAGTCAATGTCTGCAAGTAAGAA 720
OY 730 TGACGCTGTTCTGCACTCTTTTCTGCTAGAGTGTGTAAGAAACAACAGGAT 789
DB 721 TGACGCTGTTCTGCACTCTTTTCTGCTAGAGTGTGTAAGAAACAACAGGAT 780
OY 790 TAACTGAAATGTACTCAAGAGGCTTGAATGAGAGTGTGTAATTTTCCCGGAACA 849
DB 781 TAACTGAAATGTACTCAAGAGGCTTGAATGAGAGTGTGTAATTTTCCCGGAACA 840
OY 850 ACAACTTATGAGAGAGGAAATCTGCACTGAGAAAGCCTTGTCTCTCATACAGT 909
DB 841 ACAACTTATGAGAGAGGAAATCTGCACTGAGAAAGCCTTGTCTCTCATACAGT 900
OY 910 AATGGAGGTTATGACACTGATGAAATCTGCTCCGCGCAACCATATGATGAA 969
DB 901 AATGGAGGTTATGACACTGATGAAATCTGCTCCGCGCAACCATATGATGAA 960
OY 970 AAAAAACACCTAAATCTATCTCATATTCGCTTACCCCTGGGGTGGGAGAACCTTGA 1029
DB 961 AAAAAACACCTAAATCTATCTCATATTCGCTTACCCCTGGGGTGGGAGAACCTTGA 1020
OY 1030 GTCCTAAATGAAAGTGGGCGCTGTGCTGCTGTTGAGACACAGCTCTCAGAGGT 1089
DB 1021 GTCCTAAATGAAAGTGGGCGCTGTGCTGCTGTTGAGACACAGCTCTCAGAGGT 1080
OY 1090 TGAGGCTGACCTTACTCAGAGTGAATGTCCTATCATGATGATTTGATGCTGCTTC 1149
DB 1081 TGAGGCTGACCTTACTCAGAGTGAATGTCCTATCATGATGATTTGATGCTGCTTC 1140
OY 1150 CCAAGGAATAAATGTCTCTCTGTGAAACACAGAACACTGAGAGGCTTCTTCTTGA 1209
DB 1141 CCAAGGAATAAATGTCTCTCTGTGAAACACAGAACACTGAGAGGCTTCTTCTTGA 1200
OY 1210 CTTTGAATATGCTGAGATCTCTCACTTGAAGAAATGATTAATATCTCATACAGAC 1269
DB 1201 CTTTGAATATGCTGAGATCTCTCACTTGAAGAAATGATTAATATCTCATACAGAC 1260
OY 1270 TGACAGGAGCCCTCTCAGAGTGTGTAATTTGAGAAACATCAGATTAACATCTTACA 1329
DB 1261 TGACAGGAGCCCTCTCAGAGTGTGTAATTTGAGAAACATCAGATTAACATCTTACA 1319
```

```
OY 1330 AATCAGCTGATGCCCACTTAATTTGTAACATGATGATGAGGACTGCTGCTTCCA 1389
DB 1320 AATCAGCTGATGCCCACTTAATTTGTAACATGATGATGAGGACTGCTGCTTCCA 1378
OY 1390 GAGAGTGTCTTGAGAGGTTATCATTTTCCGTTTGTAACTTATTCACCAATGTCT 1449
DB 1379 GAGAGTGTCTTGAGAGGTTATCATTTTCCGTTTGTAACTTATTCACCAATGTCT 1438
OY 1450 ATCGCTGTAAGTAAATCTGTAATATACATACATTAATTAACAAATGTTCAATTA 1509
DB 1439 ATCGCTGTAAGTAAATCTGTAATATACATACATTAATTAACAAATGTTCAATTA 1498
OY 1510 AACTCTAGGAAGATTGAATTAATCTGTTACTTACATTAACATTA 1553
DB 1499 AACTCTAGGAAGATTGAATTAATCTGTTACTTACATTAACATTA 1542

RESULT 6
AAF59945
ID AAF59945 standard; cDNA; 1398 BP.
XX
AC AAF59945;
XX
DT 04-MAY-2001 (first entry)
XX
DE Human gene expression regulatory factor-related protein hnrf3-s cDNA.
XX
KW Human gene expression regulatory factor-related protein; hnrf3-s;
KW NGFI-interacting factor; haemopoietic stem cell; preparation;
KW detection; ss.
XX
OS Homo sapiens.
XX
PN CN1272543-A.
XX
PD 08-NOV-2000.
XX
PF 11-APR-2000; 2000CN-0115369.
XX
PR 11-APR-2000; 2000CN-0115369.
XX
PA (NAF-) NANFANG RES CENT STATE HUMAN GENE GROUP.
XX
PI Li N, Xiao H, Liu F.
XX
DR WPI; 2001-183596/19.
XX
DR P-PSDB; AAB60663.
XX
PT Human gene expression regulatory factor related protein and its coded
PT sequence -
XX
PS Claim 1; Page 18-19; 20pp; Chinese.
XX
CC The invention relates to a novel human gene expression regulatory
CC factor-related protein, hnrf3-s (NGFI-interacting factor, AAB60663),
CC and cDNA encoding it (AAF59945). hnrf3-s is expressed in haemopoietic
CC stem cells. The invention also relates to the preparation of hnrf3-s
CC proteins and nucleic acids, and the detection of hnrf3-s proteins and
CC nucleic acids in a sample. The present sequence represents cDNA encoding
CC hnrf3-s.
XX
SQ Sequence 1398 BP; 365 A; 331 C; 342 G; 360 T; 0 other;
XX
Query Match 86.1%; Score 1337.4; DB 22; Length 1398;
Best Local Similarity 99.5%; Pred. No. 0;
Matches 1394; Conservative 0; Mismatches 1; Indels 6; Gaps 5;
OY 9 TATCTTGTCGTCGACAGACAGACAGAGAGATTTGGTCAGAAAACCTGCTGCCG 68
DB 1 TATCTTGTCGTCGACAGACAGACAGAGAGATTTGGTCAGAAAACCTGCTGCCG 60
OY 69 ACCAGAGCAGCAGCAGCTAGTGGAGACAGGCTCTGACTCAGACTTAATGCTGTGCT 128
```


QY 248 GATTGAAAGGCTCCCTTCTCTCTGTAATGACTTTCATCCCTCCTGTTGCTGAGT 307
 DB 85 GATTGAAAGGCTCCCTTCTCTCTGTAATGACTTTCATCCCTCCTGTTGCTGAGT 144
 QY 308 TGGGACAATGTGGATTTACTGTTGGAACCAAGCCCAACACATAGTGAATAACTCTTC 367
 DB 145 TGGGACAATGTGGATTTACTGTTGGAACCAAGCCCAACACATAGTGAATAACTCTTC 204
 QY 368 CTGACCAATGACCTGACCTGAGAAAGTGAAGAGAGTCTGCAAAAAGAGGACACCTC 427
 DB 205 CTGACCAATGACCTGACCTGAGAAAGTGAAGAGAGTCTGCAAAAAGAGGACACCTC 264
 QY 428 ATTCTCTCTACCATCCGCTATCTCTCCAGCCCATGAACGCAATTAACCTGAACATATG 487
 DB 265 ATTCTCTCTACCATCCGCTATCTCTCCAGCCCATGAACGCAATTAACCTGAACATATG 324
 QY 488 AAGGAGCGCTGCTGATCCGGGCTGGAACACAGTGGATATCTCTCTCTATACA 547
 DB 325 AAGGAGCGCTGCTGATCCGGGCTGGAACACAGTGGATATCTCTCTCTATACA 384
 QY 548 GCTATGATGCTGCGGCCCGGAGGCGTCAACAATGCTGAAGGCTGAAGGCTGAGCTGT 607
 DB 385 GCTATGATGCTGCGGCCCGGAGGCGTCAACAATGCTGAAGGCTGAGCTGT 444
 QY 608 ACCCTCAGGCCATATATCTTCCAAAGCTCCCACTACCTACAGAGGAGAAACACCGA 667
 DB 445 ACCCTCAGG-CCATATATCTTCC- AAGCTCCCAATCTCCCTACAGAGAAACCCACGA 502
 QY 668 GTAGATTCAGGTTTACTACACCCCAAGCCGAGAAAGTCAATGCTCAAGTGAAGA 727
 DB 503 GTAGATTCAGGTTTACTACACCCCAAGCCGAGAAAGTCAATGCTCAAGTGAAGA 562
 QY 728 ATTGACGCTGTTCTGCTACTTCTTCTGCTAGAGTGTGTAATGAGAAACAACACG 787
 DB 563 ATTGACGCTGTTCTGCTACTTCTTCTGCTAGAGTGTGTAATGAGAAACAACG 622
 QY 788 ATTATCTGAATTTACTACAGAAAGCTTTGATGAGGTGATATTTCTTCCGGAAC 847
 DB 623 ATTATCTGAATTTACTACAGAAAGCTTTGATGAGGTGATATTTCTTCCGGAAC 682
 QY 848 AAAACAATTATCAGAAAGGGAATTTGCTCAGTGAAGAGCTTGTCTCTACATAC 907
 DB 683 AAAACAATTATCAGAAAGGGAATTTGCTCAGTGAAGAGCTTGTCTCTACATAC 742
 QY 908 GGAATGGAAGGTTATGACACACTGATGATCTGTCTCCCTGCAACCATGATGATCGA 967
 DB 743 GGAATGGAAGGTTATGACACACTGATGATCTGTCTCCCTGCAACCATGATGATCGA 802
 QY 968 ATAAAAAGACCTTAAACTATCTCATTTCCCTTACGCTTGGGTGGGAGAACCTTA 1027
 DB 803 ATAAAAAGACCTTAAACTATCTCATTTCCCTTACGCTTGGGTGGGAGAACCTTA 862
 QY 1028 GAGTCTCAAGTCAAAAGTGGGCTGTGAGTGGTGGGAGGAGCGTTCCGACGGG 1087
 DB 863 GAGTCTCAAGTCAAAAGTGGGCTGTGAGTGGTGGGAGGAGCGTTCCGACGGG 922
 QY 1088 GTTGAGGCTGACCTTACTACAGAGTGAAGATGTCCATCATATGATCTTGGATGCTCT 1147
 DB 923 GTTGAGGCTGACCTTACTACAGAGTGAAGATGTCCATCATATGATCTTGGATGCTCT 982
 QY 1148 TCCCAAGGAATTAATGTCACTCTGTGAACACAGACACATGACGAGGCTTCTTCT 1207
 DB 983 TCCCAAGGAATTAATGTCACTCTGTGAACACAGACACATGACGAGGCTTCTTCT 1042
 QY 1208 GACCTCGAATATGCTGATTTCTCACTTGGAGAAATTAATTAATTTATCCATACAG 1267
 DB 1043 GACCTCGAATATGCTGATTTCTCACTTGGAGAAATTAATTAATTTATCCATACAG 1102
 QY 1268 ACTGACAGGAGCCCTTCTGAGTGTATTAATTCAGAAACATAGAGTAAACATTCCTA 1327
 DB 1103 ACTGACAGGAGCCCTTCTGAGTGTATTAATTCAGAAACATAGAGTAAACATTCCTA 1161

QY 1328 CAATCAGCTGGATGCCCACTTAATTTGTAACATGACTCAGTGGAGCTGTGCTTC 1387
 DB 1162 CAATCAGCTGGATG-CCAACTTAATTTGTAACATGACTCAGTGGAGCTGTGCTTC 1220
 QY 1388 CAGAGAGTCTTTCGAGGATATCATATTCGCGTTTGTATTTCTTATTCACCAATGT 1447
 DB 1221 CAGAGAGTCTTTCGAGGATATCATATTCGCGTTTGTATTTCTTATTCACCAATGT 1280
 QY 1448 CTATGCTGCTGTAAGTAAAGTAAATGTAATTAATTAATTAATTAATTAATTAATTA 1507
 DB 1281 CTATGCTGCTGTAAGTAAAGTAAATGTAATTAATTAATTAATTAATTAATTAATTA 1340
 QY 1508 TAAACTGTAGGAAGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1551
 DB 1341 TAAACTGTAGGAAGATTAATTAATTAATTAATTAATTAATTAATTAATTAATTA 1384

RESULT 8
 AAS85172/c
 ID AAS85172 standard; cDNA; 1686 BP.
 XX
 AC AAS85172;
 DT 13-FEB-2002 (first entry)
 XX
 DE DNA encoding novel human diagnostic protein #20976.
 XX
 KM Human; chromosome mapping; gene mapping; gene therapy; forensic;
 KW food supplement; medical imaging; diagnostic; genetic disorder; ss.
 XX
 OS Homo sapiens.
 XX
 PN WO200175067-A2.
 PD 11-OCT-2001.
 XX
 PF 30-MAR-2001; 2001MO-US08631.
 XX
 PR 31-MAR-2000; 2000US-0540217.
 PR 23-AUG-2000; 2000US-0649167.
 XX
 PA (HYSE-) HYSQ INC.
 XX
 PI Drmanac RT, Liu C, Tang YT;
 XX
 DR WPI: 2001-639362/73.
 XX P-PSDB; ABG20985.
 XX
 PT New isolated polynucleotide and encoded polypeptides, useful in
 PT diagnostics, forensics, gene mapping, identification of mutations
 PT responsible for genetic disorders or other traits and to assess
 PT biodiversity
 XX
 PS Claim 1; SEQ ID NO 20976; 103pp; English.
 XX
 CC The invention relates to isolated polynucleotide (I) and
 CC polypeptide (II) sequences. (I) is useful as hybridisation probes,
 CC polymerase chain reaction (PCR) primers, oligomers, and for chromosome
 CC and gene mapping, and in recombinant production of (II). The
 CC polynucleotides are also used in diagnostics as expressed sequence tags
 CC for identifying expressed genes. (I) is useful in gene therapy techniques
 CC to restore normal activity of (II) or to treat disease states involving
 CC (II). (II) is useful for generating antibodies against it, detecting or
 CC quantitating a polypeptide in tissue, as molecular weight markers and as
 CC a food supplement. (II) and its binding partners are useful in medical
 CC imaging of sites expressing (II). (I) and (II) are useful for treating
 CC disorders involving aberrant protein expression or biological activity.
 CC The polypeptide and polynucleotide sequences have applications in
 CC diagnostics, forensics, gene mapping, identification of mutations
 CC responsible for genetic disorders or other traits to assess biodiversity
 CC and to produce other types of data and products dependent on DNA and
 CC amino acid sequences. AAS64197-AAS94564 represent novel human
 CC diagnostic coding sequences of the invention.

CC Note: The sequence data for this patent did not appear in the printed
CC specification, but was obtained in electronic format directly from WIPO
CC at ftp.wipo.int/pub/published_pft_sequences.
XX
XX

Sequence 1686 BP; 445 A; 397 C; 391 G; 452 T; 1 other:

Query Match 67.9%; Score 1054; DB 23; Length 1686;
Best Local Similarity 90.1%; Pred. No. 0;
Matches 1453; Conservative 0; Mismatches 100; Indels 59; Gaps 28;

QY 1 GTGATTTTATCTGTTGCTGCTGAGAGACAGACAGAGAGATGGCTGAGAAACTGC 60
DB 1627 GTGATTTTATCTGTTGCTGCTGAGAGACAGACAGAGATGGCTGAGAAACTGC 1568
QY 61 CCGGCCGACAGAGACAG 120
DB 1567 CCGGCCGACAGAGACAG 1508
QY 121 CTGTGCTGCTGTTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 180
DB 1507 CTGTGCTGCTGTTTCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCTGCT 1448
QY 181 TAGATGAGTCCGACGACGACGACGACGACGACGACGACGACGACGACGACGACG 240
DB 1447 TAGATGAGTCCGACGACGACGACGACGACGACGACGACGACGACGACGACGACG 1388
QY 241 CTTCATGAGATTTGAG 295
DB 1387 CTTCATGAGATTTGAG 1328
QY 296 TTTGCTGAGAGTTGGG---ACAATGTTGATTTAGTGGG---AACCAAGCCACACATA 350
DB 1327 TTTGCTGAGAGTTGGG---ACAATGTTGATTTAGTGGG---AACCAAGCCACACATA 1268
QY 351 ----CTGTAAATACACTCTTCTGACCAATGACCTGACGAGAA---GTGATGAGAGAG 403
DB 1267 AATGTTAAATACACTCTTCTGACCAATGACCTGACGAGAA---GTGATGAGAGAG 1208
QY 404 GTGCTGCAAAAGAA--GGCAGACCTCATCTCTCTACATCCGCTAT---CTTCGACAC 459
DB 1207 GTGCTGCAAAAGAA--GGCAGACCTCATCTCTCTACATCCGCTAT---CTTCGACAC 1148
QY 460 CATGAAGCGC---ATAACTGGAACACAT--GGAAGAGCGCTGATCCGGCTCTGG 515
DB 1147 CATGAAGCGC---ATAACTGGAACACAT--GGAAGAGCGCTGATCCGGCTCTGG 1088
QY 516 AGAAGAGAGTGGTATCT 575
DB 1087 AGAAGAGAGTGGTATCT 1028
QY 576 ACAAGTGGTGGCTAAAGGGCTTGGAGCTTGTACCTCAGGCCCATATCTTCCAAAG 635
DB 1027 ACAAGTGGTGGCTAAAGGGCTTGGAGCTTGTACCTCAGGCCCATATCTTCCAAAG 968
QY 636 CTCGCCAATACCTTACAGAGAGAAACACAGAGTGAATTCAGTAACTACACCAAG 695
DB 967 CTCGCCAATACCTTACAGAGAGAAACACAGAGTGAATTCAGTAACTACACCAAG 908
QY 696 ACCT--GGACAAAGTCAATGCT--GCAGTGAAGGAA--TTGACGGTGTCTCTCTCTCT 752
DB 907 ACCTGGGACAAAGTCAATGCT--GCAGTGAAGGAA--TTGACGGTGTCTCTCTCTCT 848
QY 753 TTTCTGCTAGAGCTGATGATGAGAGAAACACAGAGTAACTGATTAATCTAGAGAG 812
DB 847 TTTCTGCTAGAGCTGATGATGAGAGAAACACAGAGTAACTGATTAATCTAGAGAG 788
QY 813 CTTTGATGAGAGTGTGATTTTCTTCCGAAACAAACCTTATCAGAGAGGAGAA 872
DB 787 CTTTGATGAGAGTGTGATTTTCTTCCGAAACAAACCTTATCAGAGAGGAGAA 728
QY 873 TTTCTGCTAG 932
DB 727 TTTCTGCTAG 668

QY 933 ATGATCTGTCCTCCGACACATGATGATGATGATGATGATGATGATGATGATGATGATG 992
DB 667 ATGATCTGTCCTCCGACACATGATGATGATGATGATGATGATGATGATGATGATGATG 608
QY 993 ATATTCGCTTACGCTTGGGCTGGGAGAAACCTTATGATGATGATGATGATGATGATGATG 1052
DB 607 ATATTCGCTTACGCTTGGGCTGGGAGAAACCTTATGATGATGATGATGATGATGATGATG 548
QY 1053 TGTGCTGCTGCTTCT--GGAGAGAGCTTCTGAGAGGCTTGGAGG--CTGACCTTATCTCA 1109
DB 547 TGTGCTGCTGCTTCTGAG 488
QY 1110 C----AGGTGAGTGTCCATCATGATGATGATGATGATGATGATGATGATGATGATG 1161
DB 487 CAGGTGAGTGTCCATCATGATGATGATGATGATGATGATGATGATGATGATGATGAT 428
QY 1162 TGTATCTCTGCTGA---ACACAGACACATGAGAGAGAGAGAGAGAGAGAGAGAGAG 1214
DB 427 GTCAATCTCTGCTGAACACACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 368
QY 1215 GAGATATGCTGATGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1268
DB 367 GAGATATGCTGCTGAACACACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 308
QY 1269 CTGACAG 1326
DB 307 CTGACAG 248
QY 1327 ACAATATGAGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 1384
DB 247 ACAATATGAGTGTGATGATGATGATGATGATGATGATGATGATGATGATGATGATG 188
QY 1385 TTCC---AGAGAGTGTCTTGGAGGATATCATATTCCTGCTTGTATCTTATTCACCA 1441
DB 187 TTCCAGAGAGAGTGTCTTGGAGGATATCATATTCCTGCTTGTATCTTATTCACCA 128
QY 1442 AATGTTATATGCTGCTGATGATGATGATGATGATGATGATGATGATGATGATGATG 1501
DB 127 AATGTTATATGCTGCTGATGATGATGATGATGATGATGATGATGATGATGATGATG 68
QY 1502 TCATTATTAACCTTACGAGAGAGATGATGATGATGATGATGATGATGATGATGATGAT 1553
DB 67 TCATTATTAACCTTACGAGAGAGATGATGATGATGATGATGATGATGATGATGATGAT 16

RESULT 9
AAH52212
ID AAH52212 standard; cDNA; 1053 BP.
XX
XX
AAH52212:
AC 10-SEP-2001 (first entry)
XX
XX
Human AFP protein encoding cDNA sequence seq id NO:239.
XX
XX
Human: secreted protein; secretion; bacterial cell; fungal cell;
XX
XX
eukaryotic cell; fusion protein; maltose binding protein;
XX
XX
immunoglobulin constant region; polyhistidine tag; ss.
OS
XX
Homo sapiens.
XX
XX
NM0200129221-42.
XX
XX
26-APR-2001.
XX
XX
20-OCT-2000; 2000MO-US29052.
XX
XX
20-OCT-1999; 99US-0160712.
XX
XX
(ZYMO) ZYMOGENETICS INC.
XX
XX
Conklin DC, Yee DP;

| | |
|----|---|
| XX | WPI: 2001-300340/31. |
| DR | P-PSDB; AAG81361. |
| XX | |
| PT | Isolated polypeptide for directing secretion of proteins of interest from a host cell including, e.g. bacteria, includes contiguous amino acid residues of polypeptide with specified amino acids - |
| PS | |
| XX | Claim 9; Page 422-424; 617pp; English. |
| CC | AH52093 to AH53303 encode the human secreted proteins given in AAG81242 |
| CC | to AAG81453. The secreted proteins can be used for directing the |
| CC | secretion of proteins of interest from a host cell including bacteria, |
| CC | fungal cells, and cultured higher eukaryotic cells. The present invention |
| CC | also describes fusion proteins, where a secreted protein of the invention |
| CC | is operably linked via a peptide bond or peptide linker to a second |
| CC | protein selected from the group consisting of maltose binding protein, |
| CC | an immunoglobulin constant region, a polyhistidine tag and a peptide |
| CC | given in AAG81453. |
| XX | |
| SQ | Sequence 1053 BP: 279 A; 253 C; 247 G; 274 T; 0 other; |
| | |
| | Query Match 67.8%; Score 1053; DB 22; Length 1053; |
| | Best Local Similarity 100.0%; Pred. No. 0; |
| | Matches 1053; Conservative 0; Mismatches 0; Indels 0; Gaps 0; |
| OY | 245 ATGATTTGAAGCGCTCCTTTCCTTCCTTGAAATGACTTGCATCCCTCTGTTCGTGAG 304 |
| Db | 1 ATGGATTTGAAGCGCTCCTTTCCTTCCTTGAAATGACTTGCATCCCTCTGTTCGTGAG 60 |
| OY | 305 AGTTGGGCAATGTTGATTAAGTACTGGTGGAACCAACCCACCACATACTGTAATAATCACATC 364 |
| Db | 61 AGTTGGGCAATGTTGATTAAGTACTGGTGGAACCAACCCACCACATACTGTAATAATCACATC 120 |
| OY | 365 TTCTGACCAATGACCTTAGCTGAGGAAGTATGAGGAGGTGCTGCCAAAAGAAGGCAGAC 424 |
| Db | 121 TTCCTGACCAATGACCTTAGCTGAGGAAGTATGAGGAGGTGCTGCCAAAAGAAGGCAGAC 180 |
| OY | 425 CTCATTCTCTCTACCATCCGCGCTATCTTCGCGACCCATGAAAGCGCATTAACCTGGACACA 484 |
| Db | 181 CTCATTCTCTCTACCATCCGCGCTATCTTCGCGACCCATGAAAGCGCATTAACCTGGACACA 240 |
| OY | 485 TGGAAGAGCGCCCTGGTATCCGGGCTCTGGGAACAGAGTCGGTATCTCTGCTCAT 544 |
| Db | 241 TGGAAGAGCGCCCTGGTATCCGGGCTCTGGGAACAGAGTCGGTATCTCTGCTCAT 300 |
| OY | 545 ACAGCCTATGATGCTGCGCCCCAGGCGCTCAACAACATGGTTGGCTAAGAGCGCTTGAGACT 604 |
| Db | 301 ACAGCCTATGATGCTGCGCCCCAGGCGCTCAACAACATGGTTGGCTAAGAGCGCTTGAGACT 360 |
| OY | 605 TGTAACCTCCAGGCCCATACATCTCTCCAAGGCTCCCAACTACCCCTACAGAGGGAACAC 664 |
| Db | 361 TGTAACCTCCAGGCCCATACATCTCTCCAAGGCTCCCAACTACCCCTACAGAGGGAACAC 420 |
| OY | 665 CGAGTAGAATTCACAGTTAACTACACCCCAAGACCTGGACAAAGTATGTCTGCAATGAAA 724 |
| Db | 421 CGAGTAGAATTCACAGTTAACTACACCCCAAGACCTGGACAAAGTATGTCTGCAATGAAA 480 |
| OY | 725 GGAATTCAGCGGNTTCTGTCACTCTTTTCTGTAGACATGGTAAGAGGAACAACA 784 |
| Db | 481 GGAATTCAGCGGNTTCTGTCACTCTTTTCTGTAGACATGGTAAGAGGAACAACA 540 |
| OY | 785 CGGATTAATTCGAATTTGACTCAGAAAGGCTTTGATGACAGTGGTATGATTTTCTTCCGG 844 |
| Db | 541 CGGATTAATTCGAATTTGACTCAGAAAGGCTTTGATGACAGTGGTATGATTTTCTTCCGG 600 |
| OY | 845 AACAAACAACTTTATCAGAGACGGAATTTGTTCATCTGAGAAAGCTTTTGCTTCTACAT 904 |
| Db | 601 AACAAACAACTTTATCAGAGACGGAATTTGTTCATCTGAGAAAGCTTTTGCTTCTACAT 660 |
| OY | 905 ACTGGAATGGGACGGTTATGCAACACTGATGAATTTGTCTCCCTGGCAACATGATGAT 964 |
| Db | 661 ACTGGAATGGGACGGTTATGCAACACTGATGAATTTGTCTCCCTGGCAACATGATGAT 720 |

| | | | |
|-----------|---|--|------|
| QY | 965 | CGAATTAACACACACCTTAAACCTATCTCATATTCGCTTAGCCCTTGGGGTGGGAGAAC | 1024 |
| Db | 721 | CGAATTAACACACACCTTAAACCTATCTCATATTCGCTTAGCCCTTGGGGTGGGAGAAC | 780 |
| QY | 1025 | TTAAGAGTCTCAAGTCAAAAGTCGTGGCCCTGTGTCTGTGGTCTCTGAGAGCAGCTTCTGAC | 1084 |
| Db | 781 | TTAAGAGTCTCAAGTCAAAAGTCGTGGCCCTGTGTCTGTGGTCTCTGAGAGCAGCTTCTGAC | 840 |
| QY | 1085 | GGTGTGTGAGGTGACCTTACCCTACAGAGTGAATGTCATCATATCTTGGATGCT | 1144 |
| Db | 841 | GGTGTGTGAGGTGACCTTACCCTACAGAGTGAATGTCATCATATCTTGGATGCT | 900 |
| QY | 1145 | GCTTCCCAAGGAATTAATGTCTATCCTCTGTGTAAACACACAGCAACACTGAAAGAGGCTTCTT | 1204 |
| Db | 901 | GCTTCCCAAGGAATTAATGTCTATCCTCTGTGTAAACACACAGCAACACTGAAAGAGGCTTCTT | 960 |
| QY | 1205 | TCTGACCTCTGAGATATGCTGATTCCTGACATTTGGAGAAATTAATATATCTCTATCA | 1264 |
| Db | 961 | TCTGACCTCTGAGATATGCTGATTCCTGACATTTGGAGAAATTAATATATCTCTATCA | 1020 |
| QY | 1265 | GAGACTGACAGGAGCCCTCTCAGGTGGTATAA | 1297 |
| Db | 1021 | GAGACTGACAGGAGCCCTCTCAGGTGGTATAA | 1053 |
| RESULT 10 | | | |
| AAH07192 | | | |
| ID | AAH07192 | standard; CDNA: 796 BP. | |
| AC | AAH07192; | | |
| XX | | | |
| DT | 26-JUN-2001 | (first entry) | |
| XX | | | |
| DE | Human cDNA clone (5'-primer) SEQ ID NO:4027. | | |
| XX | | | |
| KM | Human; primer: detection; diagnosis; antisense therapy; gene therapy; ss. | | |
| OS | Homo sapiens. | | |
| XX | | | |
| PN | EP1074617-A2. | | |
| PD | 07-FEB-2001. | | |
| XX | | | |
| PF | 28-JUL-2000; 2000EP-0116126. | | |
| XX | | | |
| PR | 29-JUL-1999; 99JP-0248036. | | |
| PR | 27-AUG-1999; 99JP-0300253. | | |
| PR | 11-JAN-2000; 2000JP-0118776. | | |
| PR | 02-MAY-2000; 2000JP-0188767. | | |
| PR | 09-JUN-2000; 2000JP-0241899. | | |
| XX | | | |
| PA | (HELI-) HELIX RES INST. | | |
| PI | Ota T, Isogai T, Nishikawa T, Hayashi K, Saito K, Yamamoto J; | | |
| PI | Ishii S, Sugiyama T, Wakamatsu A, Nagai K, Otsuki T; | | |
| DR | WPI; 2001-318749/34. | | |
| XX | | | |
| PT | Primer sets for synthesizing polynucleotides, particularly the 5602 | | |
| PR | full-length cDNAs defined in the specification, and for the detection | | |
| PR | and/or diagnosis of the abnormality of the proteins encoded by the | | |
| PT | full-length cDNAs - | | |
| XX | | | |
| PS | Claim 1; SEQ ID 4027; 2537bp + CD ROM; English. | | |
| XX | | | |
| CC | The present invention describes primer sets for synthesizing 5602 | | |
| CC | full-length cDNAs defined in the specification. Where a primer set | | |
| CC | comprises: (a) an oligo-dr primer and an oligonucleotide complementary | | |
| CC | to the complementary strand of a polynucleotide which comprises one of | | |
| CC | the 5602 nucleotide sequences defined in the specification, where the | | |
| CC | oligonucleotide comprises at least 15 nucleotides; or (b) a combination | | |
| CC | of an oligonucleotide comprising a sequence complementary to the | | |

complementary strand of a polynucleotide which comprises a 5'-end sequence and an oligonucleotide comprising a sequence complementary to a polynucleotide which comprises at least 15 nucleotides and the combination of the 5'-end sequence/3'-end sequence is selected from those defined in the specification. The primer sets can be used in antisense therapy and in gene therapy. The primers are useful for synthesizing polynucleotides, particularly full-length cDNAs. The primers are also useful for the detection and/or diagnosis of the abnormality of the proteins encoded by the full-length cDNAs. The primers allow obtaining of the full-length cDNAs easily without any specialised methods. AAH03166 to AAH13628 and AAH13633 to AAH18742 represent human cDNA sequences; AAH92446 to AAH95893 represent human amino acid sequences; and AAH13629 to AAH13632 represent oligonucleotides, all of which are used in the exemplification of the present invention.

XX Sequence 796 BP; 192 A; 204 C; 202 G; 195 T; 3 other;

Query Match 46.7%; Score 725; DB 22; Length 796;

Best Local Similarity 98.4%; Pred. No. 1.3e-213;

Matches 762; Conservative 0; Mismatches 8; Indels 4; Gaps 3;

1 GTGATTTGTTATCTGTCGTCAGAGACACAGAGAGATGGTGCAGAAAACCTGC 60
 27 GTGATTTGTTATCTGTCGTCAGAGACACAGAGAGATGGTGCAGAAAACCTGC 86
 61 CCTGCGCAGACAGACAGAGAGATGGTGCAGAGATGGTGCAGAGATGGTGCAG 120
 87 CCTGCGCAGACAGACAGAGAGATGGTGCAGAGATGGTGCAGAGATGGTGCAG 146
 121 CTGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCG 180
 147 CTGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCGTCG 206
 181 TAGATGAGTCCCGCAGACAGATGGTGCAGAGATGGTGCAGAGATGGTGCAG 240
 207 TAGATGAGTCCCGCAGACAGATGGTGCAGAGATGGTGCAGAGATGGTGCAG 266
 241 CTTATGATGATTTGAAGGCTCTCTTCTCTTGAATGATTTGATGATTTGATGAT 300
 267 CTTATGATGATTTGAAGGCTCTCTTCTCTTGAATGATTTGATGATTTGATGAT 326
 301 TGAGATGATGATTTGAAGGCTCTCTTCTCTTGAATGATTTGATGATTTGATG 360
 327 TGAGATGATGATTTGAAGGCTCTCTTCTCTTGAATGATTTGATGATTTGATG 386
 361 ACTTCTCTGACATGACCTGATGAGAGATGATGAGAGATGATGAGAGATGATG 420
 387 ACTTCTCTGACATGACCTGATGAGAGATGATGAGAGATGATGAGAGATGATG 446
 421 AGACCTATTTCT 480
 447 AGACCTATTTCT 506
 481 CACATGGAAG 540
 507 CACATGGAAG 566
 541 TCATACAG 600
 567 TCATACAG 626
 601 AGCTTGTACCTCCAG 660
 627 AGCTTGTACCTCCAG 685
 661 CCACCGAGTGAATTAAGTGAATTAAGTGAATTAAGTGAATTAAGTGAATTAAGT 720
 686 CCACCGAGTGAATTAAGTGAATTAAGTGAATTAAGTGAATTAAGTGAATTAAGT 744
 721 GAAAGGATGAG 774
 745 GAAAGGATGAG 796

RESULT 11

AAH23953 standard; cDNA; 462 BP.

XX AAH23953;

DT 07-DEC-2001 (first entry)

XX Human breast cancer expressed polynucleotide 16410.

XX Human breast cancer; cell marker; cytostatic; ss.

XX Homo sapiens.

XX WO200151628-A2.

XX 19-JUL-2001.

XX 10-JAN-2001; 2001WO-US00798.

XX 14-JAN-2000; 2000US-0176077.

XX 14-MAR-2000; 2000US-0189167.

XX 24-MAR-2000; 2000US-0192099.

XX 29-MAR-2000; 2000US-0193480.

XX 15-MAY-2000; 2000US-0205230.

XX 09-JUN-2000; 2000US-0211315.

XX 25-JUL-2000; 2000US-0220534.

XX (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC.

XX Lillie J, Xu Y, Wang Y, Steilmann K;

XX WPI: 2001-451856/48.

XX New peptide useful as a marker for the diagnosis of breast cancer

XX Claim 1; Page 3004; 3695pp; English.

XX The invention relates to human breast cancer expressed polynucleotides

XX (AAH07544-AAH26789) and methods of assessing whether a patient is

XX afflicted with breast cancer by examining the correlation between the

XX expression of certain markers and the cancerous state of breast cells.

XX The polynucleotides and encoded polypeptides are potential markers for

XX detecting, diagnosing, monitoring, characterizing, treating and encoded

XX polypeptides are also useful for isolating compounds with cytostatic

XX activity.

XX Sequence 462 BP; 103 A; 126 C; 118 G; 115 T; 0 other;

XX Query Match 27.3%; Score 424; DB 22; Length 462;

XX Best Local Similarity 100.0%; Pred. No. 1.0e-120;

XX Matches 424; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

188 GTCCCGACAG 247
 39 GTCCCGACAG 98
 248 GATTTGAAGGCT 307
 99 GATTTGAAGGCT 158
 308 TGGGACAAATGTTGATTTACTGTGGAACCAAGCCACACATCTGTAAATACACTTC 367
 159 TGGGACAAATGTTGATTTACTGTGGAACCAAGCCACACATCTGTAAATACACTTC 218
 368 CTGACCAATGACCTGACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 427
 219 CTGACCAATGACCTGACAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAGAG 278
 428 ATTCTCTCTACATCCGCTATCTTCCGACCATGAAGGCGCATTAACCTGGAAACATGG 487

```
Db      279 ATTCTCTCTACCATCGCCTATCTTCACCCATGAAAGCATTAACCTGGAAACATATGG 338
OY      488 AAGGAGCGCGCTGATGATCCGGGCTCGAGAACAGAGTGGTATCTACTCTCCATACA 547
Db      339 AAGGAGCGCGCTGATGATCCGGGCTCGAGAACAGAGTGGTATCTACTCTCCATACA 398
OY      548 GCCTATGATGTCGCGCCCGAGGCGCTCAACAACCTGGTGGCTAAAGGGCTTGGAGCTTGT 607
Db      399 GCCTATGATGTCGCGCCCGAGGCGCTCAACAACCTGGTGGCTAAAGGGCTTGGAGCTTGT 458
OY      608 ACCT 611
Db      459 ACCT 462

RESULT 12
AAK78763
ID      AAK78763 standard; DNA; 14969 BP.
XX
AC      AAK78763;
XX
DT      07-NOV-2001 (first entry)
XX
DE      Human immune/haematopoietic antigen genomic sequence SEQ ID NO:33575.
XX
KW      Human; immune; haematopoietic; immune/haematopoietic antigen; cancer;
KM      cytostatic; gene therapy; vaccine; metastasis; ds.
XX
OS      Homo sapiens.
XX
PN      WO200157182-A2.
XX
PD      09-AUG-2001.
XX
PF      17-JAN-2001; 2001WO-US01354.
XX
PR      31-JAN-2000; 2000US-0179065.
PR      04-FEB-2000; 2000US-0180628.
PR      24-FEB-2000; 2000US-0184664.
PR      02-MAR-2000; 2000US-0186350.
PR      16-MAR-2000; 2000US-0189874.
PR      17-MAR-2000; 2000US-0190076.
PR      18-APR-2000; 2000US-0198123.
PR      09-MAY-2000; 2000US-0205515.
PR      07-JUN-2000; 2000US-0209467.
PR      28-JUN-2000; 2000US-0214886.
PR      30-JUN-2000; 2000US-0215135.
PR      07-JUL-2000; 2000US-0216647.
PR      07-JUL-2000; 2000US-0216880.
PR      11-JUL-2000; 2000US-0217487.
PR      11-JUL-2000; 2000US-0217496.
PR      14-JUL-2000; 2000US-0218290.
PR      26-JUL-2000; 2000US-0220963.
PR      26-JUL-2000; 2000US-0220964.
PR      14-AUG-2000; 2000US-0224518.
PR      14-AUG-2000; 2000US-0224519.
PR      14-AUG-2000; 2000US-0225213.
PR      14-AUG-2000; 2000US-0225214.
PR      14-AUG-2000; 2000US-0225266.
PR      14-AUG-2000; 2000US-0225267.
PR      14-AUG-2000; 2000US-0225268.
PR      14-AUG-2000; 2000US-0225270.
PR      14-AUG-2000; 2000US-0225447.
PR      14-AUG-2000; 2000US-0225757.
PR      14-AUG-2000; 2000US-0225758.
PR      14-AUG-2000; 2000US-0225759.
PR      18-AUG-2000; 2000US-0226279.
PR      22-AUG-2000; 2000US-0226681.
PR      22-AUG-2000; 2000US-0226688.
PR      22-AUG-2000; 2000US-0227182.
PR      23-AUG-2000; 2000US-0227009.
PR      30-AUG-2000; 2000US-0228924.
PR      01-SEP-2000; 2000US-0229287.
PR      01-SEP-2000; 2000US-0229343.
PR      01-SEP-2000; 2000US-0229344.
PR      01-SEP-2000; 2000US-0229345.
PR      05-SEP-2000; 2000US-0229509.
PR      05-SEP-2000; 2000US-0229513.
PR      06-SEP-2000; 2000US-0230437.
PR      06-SEP-2000; 2000US-0230438.
PR      08-SEP-2000; 2000US-0231242.
PR      08-SEP-2000; 2000US-0231243.
PR      08-SEP-2000; 2000US-0231244.
PR      08-SEP-2000; 2000US-0231413.
PR      08-SEP-2000; 2000US-0231414.
PR      08-SEP-2000; 2000US-0232080.
PR      08-SEP-2000; 2000US-0232081.
PR      12-SEP-2000; 2000US-0231968.
PR      14-SEP-2000; 2000US-0232397.
PR      14-SEP-2000; 2000US-0232398.
PR      14-SEP-2000; 2000US-0232399.
PR      14-SEP-2000; 2000US-0232400.
PR      14-SEP-2000; 2000US-0232401.
PR      14-SEP-2000; 2000US-0233063.
PR      14-SEP-2000; 2000US-0233064.
PR      14-SEP-2000; 2000US-0233065.
PR      21-SEP-2000; 2000US-0234223.
PR      21-SEP-2000; 2000US-0234274.
PR      25-SEP-2000; 2000US-0234977.
PR      25-SEP-2000; 2000US-0234998.
PR      26-SEP-2000; 2000US-0235484.
PR      27-SEP-2000; 2000US-0235834.
PR      27-SEP-2000; 2000US-0235836.
PR      29-SEP-2000; 2000US-0236327.
PR      29-SEP-2000; 2000US-0236367.
PR      29-SEP-2000; 2000US-0236368.
PR      29-SEP-2000; 2000US-0236369.
PR      29-SEP-2000; 2000US-0236370.
PR      02-OCT-2000; 2000US-0236802.
PR      02-OCT-2000; 2000US-0237037.
PR      02-OCT-2000; 2000US-0237038.
PR      02-OCT-2000; 2000US-0237039.
PR      02-OCT-2000; 2000US-0237040.
PR      13-OCT-2000; 2000US-0239835.
PR      13-OCT-2000; 2000US-0239837.
PR      20-OCT-2000; 2000US-0240960.
PR      20-OCT-2000; 2000US-0241221.
PR      20-OCT-2000; 2000US-0241785.
PR      20-OCT-2000; 2000US-0241786.
PR      20-OCT-2000; 2000US-0241787.
PR      20-OCT-2000; 2000US-0241808.
PR      20-OCT-2000; 2000US-0241809.
PR      20-OCT-2000; 2000US-0241826.
PR      01-NOV-2000; 2000US-0244617.
PR      08-NOV-2000; 2000US-0246474.
PR      08-NOV-2000; 2000US-0246475.
PR      08-NOV-2000; 2000US-0246476.
PR      08-NOV-2000; 2000US-0246477.
PR      08-NOV-2000; 2000US-0246478.
PR      08-NOV-2000; 2000US-0246523.
PR      08-NOV-2000; 2000US-0246524.
PR      08-NOV-2000; 2000US-0246525.
PR      08-NOV-2000; 2000US-0246526.
PR      08-NOV-2000; 2000US-0246527.
PR      08-NOV-2000; 2000US-0246528.
PR      08-NOV-2000; 2000US-0246532.
PR      08-NOV-2000; 2000US-0246609.
PR      08-NOV-2000; 2000US-0246610.
PR      08-NOV-2000; 2000US-0246611.
PR      08-NOV-2000; 2000US-0246613.
PR      17-NOV-2000; 2000US-0249207.
PR      17-NOV-2000; 2000US-0249208.
PR      17-NOV-2000; 2000US-0249209.
PR      17-NOV-2000; 2000US-0249210.
PR      17-NOV-2000; 2000US-0249211.
```

[illegible]

| | | | |
|-----------|--|---|-------|
| Db | 14192 | TCACCTTGGAGAAATAGATTAATATATATCTCTTCAGACTGACAGAGACCCCTTTCAGGT | 1425 |
| Qy | 1291 | GGATTAATATTCGAGAAACATCAGGATTAACACATTCCTTCAAAATCAGCTGGATGCCAACTT | 1350 |
| Db | 14252 | GGTATTAATTCGAGAAACATCAGGATTAACACATTCCTTCAAAATCAGCTGGATGCCAACTT | 1430 |
| Qy | 1351 | AAATTTGTAACATGACGACGAGGAGGACGCGGTGCTTCACAGAGGTGCTTCGAGGGTATC | 1410 |
| Db | 14310 | AAATTTGTAACATGACGACGAGGAGGACGCGGTGCTTCACAGAGGTGCTTCGAGGGTATC | 1436 |
| Qy | 1411 | ATCATTTCCGGTTTGTATTAATCTTATTCACCAAAATGTTCTATTCGCTCTGAAGGTAAACTG | 1470 |
| Db | 14370 | ATCATTTCCGGTTTGTATTAATCTTATTCACCAAAATGTTCTATTCGCTCTGAAGGTAAACTG | 1442 |
| Qy | 1471 | TAAATTAATCTTCCCATTTTAATTAACAATGTCTATTATTAACCTTAGCAAAAGATGTGATA | 1530 |
| Db | 14430 | TAAATTAATCTTCCCATTTTAATTAACAATGTCTATTATTAACCTTAGCAAAAGATGTGATA | 1448 |
| Qy | 1531 | AAATCTGTTTACTTAACATTC | 1551 |
| Db | 14490 | AAATCTGTTTACTTAACATTC | 14510 |
| RESULT 13 | | | |
| ID | AA15105 | standard; cDNA: 514 BP. | |
| XX | AA15105; | | |
| AC | AA15105; | | |
| XX | 07-DEC-2001 (first entry) | | |
| DT | 07-DEC-2001 (first entry) | | |
| XX | Human breast cancer expressed polynucleotide 7562. | | |
| DE | Human breast cancer; cell marker; cytostatic; ss. | | |
| XX | Human; breast cancer; cell marker; cytostatic; ss. | | |
| KW | Homo sapiens. | | |
| XX | Homo sapiens. | | |
| OS | Homo sapiens. | | |
| XX | WO200151628-A2. | | |
| PN | WO200151628-A2. | | |
| XX | 19-JUL-2001. | | |
| PD | 19-JUL-2001. | | |
| XX | 10-JAN-2001; 2001WO-US00798. | | |
| PF | 10-JAN-2001; 2001WO-US00798. | | |
| XX | 14-JAN-2000; 2000US-0176077. | | |
| PR | 14-MAR-2000; 2000US-0189167. | | |
| XX | 24-MAR-2000; 2000US-0192099. | | |
| PR | 29-MAR-2000; 2000US-0193480. | | |
| XX | 15-MAY-2000; 2000US-0205230. | | |
| PR | 09-JUN-2000; 2000US-0211315. | | |
| XX | 25-JUL-2000; 2000US-0220534. | | |
| PA | (MILL-) MILLENNIUM PREDICTIVE MEDICINE INC. | | |
| XX | Lillie J, Xu Y, Wang Y, Steinmann K; | | |
| PI | WPI; 2001-451856/48. | | |
| XX | New peptide useful as a marker for the diagnosis of breast cancer | | |
| XX | Claim 1; Page 1361; 3695pp; English. | | |
| PS | The invention relates to human breast cancer expressed polynucleotides | | |
| XX | (AA107544-AA126789) and methods of assessing whether a patient is | | |
| CC | afflicted with breast cancer by examining the correlation between the | | |
| XX | expression of certain markers and the cancerous state of breast cells. | | |
| CC | The polynucleotides and encoded polypeptides are potential markers for | | |
| XX | detecting, diagnosing, monitoring, characterising treating and | | |
| CC | potentially preventing breast cancer. The polynucleotides and encoded | | |
| XX | polypeptides are also useful for isolating compounds with cytostatic | | |
| CC | activity. | | |
| XX | Sequence 514 BP; 113 A; 141 C; 130 G; 126 T; 4 other; | | |

Query Match 25.6%; Score 396.8; DB 22; Length 514;
 Best Local Similarity 98.6%; Pred. No. 4.6e-112;
 Matches 420; Conservative 0; Mismatches 4; Indels 2; Gaps 2;

QY 168 GTCCCGACGACGATCGGCTTTAGATTCCTGATGATGATTCCTCCGCTTCATG 247
 DB 65 GTCCCGACGACGATCGGCTTTAGATTCCTGATGATGATTCCTCCGCTTCATG 124
 QY 248 GATTGAGAGGCTCTCTCTCTCTCTGATGATGATTCCTCCGCTTCATG 307
 DB 125 GATTGAGAGGCTCTCTCTCTCTGATGATGATTCCTCCGCTTCATG 184
 QY 308 TGGGACAAATGTTGATTTACTGTTGAGAACCCACACATATCTAATACACTCTTC 367
 DB 185 TGGGACAAATGTTGATTTACTGTTGAGAACCCACACATATCTAATACACTCTTC 244
 QY 368 CTGACCAATGACCTGATGAGAAATGATGAGAGGCTCTCCAAAAGAGCAGACCTTC 427
 DB 245 CTGACCAATGACCTGATGAGAAATGATGAGAGGCTCTCCAAAAGAGCAGACCTTC 304
 QY 428 ATTCTCTCTACATCCGCTATCTTCGACCATGAGGATTAACCTGGAACATG 487
 DB 305 ATTCTCTCTACATCCGCTATCTTCGACCATGAGGATTAACCTGGAACATG 364
 QY 488 AAGGAGCGCTGATGATGAGGCTCTGAGAAC-AGATGCTATCTACTCTCTCATAC 546
 DB 365 AAGGAGCGCTGATGATGAGGCTCTGAGAACAAAGCGGTATCTACTCTCATAC 424
 QY 547 AGCCTATGATGCTGGGCCCCGAGGGG-TCACACATGTTGGCTAAAGGCTTGAGCTT 605
 DB 425 AGCCTATGATGCTGGGCCCCGAGGGGCTTCACACATGTTGGCTAAAGGCTTGAGCTT 484
 QY 606 GTACTT 611
 DB 485 GTACTT 490

RESULT 14
 AAS44816
 ID AAS44816 standard; DNA; 513 BP.
 XX AAS44816;
 AC 18-DEC-2001 (first entry)
 XX 18-DEC-2001 (first entry)
 DE Human contig polynucleotide sequence #69.
 XX Mammal; human; rhesus monkey; baker's yeast; fission yeast; Norway rat;
 KW mouse; Chinese hamster; African clawed frog; fruit fly; dog; leukaemia;
 KW cancer; lymphoma; neuroblastoma; autoimmune disorder; cell proliferation;
 KW nervous system disorder; inflammatory disorder; cell differentiation; ds;
 KW angiogenesis; stem cell growth factor; actin; inhibin; cartilage; burn;
 KW genetic disorder; bone regeneration; tendon; ligament; tissue repair;
 KW cytoskeletal; antineoplastic; antitubercular; vulnary; antineoplastic;
 KW antibacterial; immunosuppressive; vasotropic; antiparkinsonian;
 KW neoprotective; osteoprotic; antidiabetic; antiallergic;
 KW immunostimulant; analgesic; gene therapy.
 XX Homo sapiens.
 OS Synthetic.
 XX WO20016834-A2.
 PN 07-SEP-2001.
 PD 26-FEB-2001; 2001WO-US04926.
 XX 28-FEB-2000; 2000US-0515126.
 PR 18-MAY-2000; 2000US-0577409.
 PR 17-JUN-2000; 2000US-0597707.
 PR 14-JUL-2000; 2000US-0616807.
 PR 19-SEP-2000; 2000US-0664641.

XX (HYSE-) HYSEQ INC.
 PA Xue Y, Liu C, Zhou P, Asundi V, Zhang J, Zhao Q, Ren F;
 PI Tang AJ, Yang Y, Wehrman T, Wang J, Ma Y, Wang D, Chen R, Xu C;
 PI Drmanac R;
 DR WPI: 2001-589862/66.
 DR P-PSDB: AAU27916.
 XX Novel polypeptides and nucleic acids obtained from cDNA libraries
 PT prepared from various human tissues, for diagnosis, treatment of
 PT cancer, neurological, inflammatory disorders and for use in arrays for
 PT detection
 PS Claim 1: SEQ ID NO 413; 153pp; English.
 XX Sequences AAS44576-AAS44919 represent full-length polynucleotides and
 CC contig polynucleotides encoding polypeptides of the invention. The DNA
 CC and protein sequences are useful for the treatment, diagnosis and
 CC prevention of various types of disorder in a mammalian subject such as a
 CC human, dog, monkey, mouse, hamster or rat. The disorders include cancers
 CC such as leukaemia, lymphoma and neuroblastoma, autoimmune disorders such
 CC as multiple sclerosis, connective tissue disease, rheumatoid arthritis,
 CC diabetes mellitus, allergic rhinitis, asthma and eczema, nervous system
 CC disorders such as Parkinson's disease, Alzheimer's disease, Huntington's
 CC chorea, amyotrophic lateral sclerosis, spinal muscular atrophy and
 CC Wernicke disease, inflammatory disorders such as nephritis, Crohn's
 CC disease, ischaemia-reperfusion injury, shock, sepsis and inflammatory
 CC bowel disease. The sequences exhibit activity relating to angiogenesis,
 CC cell proliferation, cell differentiation, stem cell growth factor,
 CC activin or inhibin. Therefore, they can be used to manipulate stem cells
 CC in culture to give rise to neuroepithelial cells that can be used to
 CC augment or replace cells damaged by illness, accidental damage or genetic
 CC disorders. The sequences may also be used for regeneration of bone,
 CC cartilage, tendons and ligaments and in tissue repair and burn healing.
 CC Note: Some sequences for this patent did not form part of the printed
 CC specification, but were obtained in electronic format directly from WIPO
 CC at ftp.wipo.int/pub/published_pcl_sequences.
 CC XX

Sequence 513 BP; 122 A; 144 C; 114 G; 131 T; 2 other;
 SQ

Query Match 22.9%; Score 355.6; DB 22; Length 513;
 Best Local Similarity 93.8%; Pred. No. 2.7e-99;
 Matches 392; Conservative 0; Mismatches 24; Indels 2; Gaps 2;

QY 204 GGTGTGATGATTCCTGATGATGATTCCTCCGCTTCATGATGATGAGGCTCTCC 263
 DB 86 GGTGTGATGATTCCTGATGATGATTCCTCCGCTTCATGATGATGAGGCTCTCC 145
 QY 264 TTTCTCTCTGATGATGATTCCTCCGCTTCATGATGATGAGGCTCTCC 323
 DB 146 TTTCTCTCTGATGATGATTCCTCCGCTTCATGATGATGAGGCTCTCC 205
 QY 324 TACTGTGATGATGATGATGATTCCTCCGCTTCATGATGATGAGGCTCTCC 383
 DB 206 TACTGTGATGATGATGATGATTCCTCCGCTTCATGATGATGAGGCTCTCC 265
 QY 384 CTGAGAGTGTGATGATGATGATTCCTCCGCTTCATGATGATGAGGCTCTCC 443
 DB 266 CTGAGAGTGTGATGATGATGATTCCTCCGCTTCATGATGATGAGGCTCTCC 325
 QY 444 CGCTATCTCTGATGATGATTCCTCCGCTTCATGATGATGAGGCTCTCC 503
 DB 326 CGCTATCTCTGATGATGATTCCTCCGCTTCATGATGATGAGGCTCTCC 385
 QY 504 TCCGGCTCTGATGATGATGATTCCTCCGCTTCATGATGATGAGGCTCTCC 562
 DB 386 TCCGGCTCTGATGATGATGATTCCTCCGCTTCATGATGATGAGGCTCTCC 445
 QY 563 CCCAGAGGCTGATGATGATTCCTCCGCTTCATGATGATGAGGCTCTCC 619
 DB 446 CCCAGAGGCTGATGATGATTCCTCCGCTTCATGATGATGAGGCTCTCC 503

RESULT 15
 ABX45683
 ID ABX45683 standard; CDNA; 394 BP.
 XX
 AC ABX45683;
 XX
 DT 21-FEB-2003 (first entry)
 DE Bovine EST associated with lactation/muscle/fat deposition #10848.
 XX
 KW Bovine; ss; EST; expressed sequence tag; lactation; LMPD;
 XX muscle deposition; fat deposition; genome mapping; gene identification;
 XX gene analysis; cattle breeding.
 OS Bos Taurus.
 XX
 PN US2002137139-A1.
 PD
 XX 26-SEP-2002.
 XX
 PF 24-SEP-2001; 2001US-0960352.
 XX
 PR 12-JAN-1999; 99US-115707P.
 XX
 PR 11-JAN-2000; 2000US-0480902.
 XX
 PA (BYAT/) BYATT J C.
 PA (MATH/) MATHIALAGAN N.
 PA (TAON/) TAO N.
 PA (WARF/) WARREN W C.
 PI Byatt JC, Mathialagan N, Tao N, Warren WC;
 XX
 DR MPI; 2003-110599/10.
 XX
 PT New nucleic acid associated with lactation, and muscle and fat
 XX deposition, useful for genome mapping, gene identification and
 XX analysis, cattle breeding, or for genetically improving cattle
 XX
 PS Claim 2; SEQ ID No 10848; 245bp; English.
 XX
 XX
 CC The invention relates to a purified nucleic acid molecule associated with
 CC lactation or muscle and fat deposition (designated LMPD), derived
 CC from cattle, and the LMPD nucleic acid can specifically hybridise to a
 CC second nucleic acid molecule comprising any of 15112 nucleotide
 CC sequences, appearing as ABX4836-ABX49947, or complements of them.
 CC Also included are: (1) a transformed cell having a nucleic acid
 CC comprising an LMPD nucleic acid linked to a promoter and a 3' non-
 CC translated sequence that functions in the cell to cause termination of
 CC transcription and addition of polyadenylated ribonucleotides to a 3' end
 CC of the mRNA molecule; and (2) determining a level or pattern of a
 CC molecule in a bovine cell or tissue comprising: (a) incubating a marker
 CC nucleic acid (comprising any of the 15112 nucleic acid sequences or its
 CC complement or fragment) with a complementary nucleic acid molecule
 CC obtained from the bovine cell or tissue, where hybridisation between the
 CC marker nucleic acid and the complementary nucleic acid permits the
 CC detection of the molecule; and (b) detecting the level or pattern of the
 CC complementary nucleic acid, where the detection of the complementary
 CC nucleic acid is predictive of the level or pattern of the molecule.
 CC The LMPD nucleic acid is used for determining a level or pattern
 CC of a molecule in a bovine cell or tissue. It is useful for genome
 CC mapping, gene identification and analysis, cattle breeding, preparation
 CC of constructs for use in cattle gene expression, or for genetically
 CC improving cattle. The present sequence is one of the 15112 bovine
 CC LMPD EST (expressed sequence tag) nucleic acids.
 CC Note: The present sequence was not shown in the specification but
 CC was obtained in electronic format from the USPTO web site:
 CC seqdata.uspto.gov/sequence.html?docID=20020137139.
 XX
 XX Sequence 394 BP; 83 A; 117 C; 94 G; 100 T; 0 other;

[illegible]

Search completed: August 23, 2003, 12:35:11
Job time : 347 secs

| Query match | 18.68; | Score 288.2; | DB 25; | Length 394; |
|-------------|--------|--------------|--------|-------------|
|-------------|--------|--------------|--------|-------------|

THIS PAGE BLANK (USPTO)